87 results on '"Rodríguez Palomares JF"'
Search Results
2. Abstracts
- Author
-
Doulaptsis, C, Masci, PG, Goetschalckx, K, Janssens, S, Bogaert, J, Ferreira, VM, Piechnik, SK, DallArmellina, E, Karamitsos, TD, Francis, JM, Ntusi, N, Holloway, C, Choudhury, RP, Kardos, A, Robson, MD, Friedrich, MG, Neubauer, S, Miszalski-Jamka, T, Sokolowska, B, Szczeklik, W, Karwat, K, Miszalski-Jamka, K, Belzak, K, Malek, L, Mazur, W, Kereiakes, DJ, Jazwiec, P, Musial, J, Pedrotti, P, Masciocco, G, DAngelo, L, Milazzo, A, Quattrocchi, G, Zanotti, F, Frigerio, M, Roghi, A, Rimoldi, O, Kaasalainen, T, Kivistö, S, Holmström, M, Pakarinen, S, Hänninen, H, Sipilä, O, Lauerma, K, Banypersad, S.M, Fontana, M, Maestrini, V, Sado, D.M, Pinney, J, Wechalekar, A.D, Gillmore, J.D, Lachmann, H, Hawkins, P.N, Moon, J.C, Barone-Rochette, G, Pierard, S, Seldrum, S, de Ravensteen, CM, Melchior, J, Maes, F, Pouleur, A-C, Vancraeynest, D, Pasquet, A, Vanoverschelde, J-L, L Gerber, B, Captur, G, Muthurangu, V, Flett, AS, Wilson, R, Barison, A, Anderson, S, Cook, C, Sado, DM, McKenna, WJ, Mohun, TJ, Elliott, PM, Moon, JC, Pepe, A, Meloni, A, Gulino, L, Rossi, G, Paci, C, Spasisno, A, keilberg, P, Restaino, G, Resta, MC, Positano, V, lombardi, M, Reiter, U, Reiter, G, Kovacs, G, Schmidt, A, Olschewski, H, Fuchsjäger, M, Macmillan, A, Dabir, D, Rogers, T, Monaghan, M, Nagel, E, Puntmann, V, Semaan, E, Spottiswoode, B, Freed, B, Carr, M, Wasielewski, M, Fortney-Campione, K, Shah, S, Carr, J, Markl, M, Collins, J, Sung, YM, Hinojar, R, Ucar, EA, Dabir, D, Voigt, T, Gaddum, N, Schaeffter, T, Nagel, E, Puntmann, VO, Dabir, D, Rogers, T, Ucar, EA, Kidambi, A, Plein, S, Gebker, R, Schnackenburg, B, Voigt, T, Schaeffter, T, Nagel, E, Puntmann, VO, McAlindon, E, Bucciarelli-Ducci, C, Sado, D, Maestrini, V, Piechnik, S, Porter, J, Yamamura, J, Fischer, R, Moon, J, Symons, R, Doulaptsis, C, Masci, P.G, Goetschalckx, K, Dymarkowski, S, Janssens, S, Bogaert, J, Yalin, K, Golcuk, E, Ozer, CS, Buyukbayrak, H, Yilmaz, R, Dursun, M, Bilge, AK, Adalet, K, Reinstadler, SJ, Klug, G, Feistritzer, HJ, Mayr, A, Harrasser, B, Krauter, L, Mair, J, Schocke, MF, Pachinger, O, Metzler, B, Rigolli, M, To, A, Edwards, C, Ding, P, Christiansen, J, Rodríguez-Palomares, JF, Ortiz, JT, Bucciarelli, C, Lee, D, Wu, E, Bonow, RO, Karwat, K, Tomala, M, Miszalski-Jamka, K, Licholaj, S, Mazur, W, Kereiakes, DJ, Nessler, J, Zmudka, K, Jazwiec, P, Miszalski-Jamka, T, Peltonen, J, Kaasalainen, T, Kivistö, S, Holmström, M, Lauerma, K, Rutz, T, Meierhofer, C, Martinoff, S, Ewert, P, Hess, J, Stern, H, Fratz, S, Groarke, JD, Waller, AH, Blankstein, R, Kwong, RY, Steigner, M, Alizadeh, Z, Alizadeh, A, Khajali, Z, Mohammadzadeh, A, Kaykhavani, A, Heidarali, M, Singh, A, Bekele, S, Gunarathne, A, Khan, J, Nazir, SN, Steadman, CD, Kanagala, P, Horsfield, MA, McCann, GP, Duncan, RF, Dundon, BK, Nelson, AJ, Williams, K, Carbone, A, Worthley, MI, Zaman, A, Worthley, SG, Monney, P, Piccini, D, Rutz, T, Vincenti, G, Koestner, S, Stuber, M, Schwitter, J, Gripari, P, Maffessanti, F, Pontone, G, Andreini, D, Bertella, E, Mushtaq, S, Caiani, EG, Pepi, M, El ghannudi, S, Nghiem, A, Germain, P, Jeung, M-J, Roy, C, Gangi, A, Nucifora, G, Muser, D, Masci, PG, Barison, A, Piccoli, G, Rebellato, L, Puppato, M, Gasparini, D, Lombardi, M, Proclemer, A, Nucifora, G, Muser, D, Masci, PG, Barison, A, Piccoli, G, Rebellato, L, Puppato, M, Gasparini, D, Lombardi, M, Proclemer, A, Pöyhönen, P, Kivistö, S, Holmströn, M, Hänninen, H, Thorning, C, Bickelhaupt, S, Kampmann, C, Wentz, KU, Widmer, U, Juli, CF, Miszalski-Jamka, K, Klys, J, Glowacki, J, Kijas, M, Miszalski-Jamka, T, Adamczyk, T, Kwiecinski, R, Bogucka-Czapska, J, Ozaist, M, Mazur, W, Kluczewska, E, Kalarus, Z, Kukulski, T, Karakus, G, Marzluf, B, Bonderman, D, Tufaro, C, Pfaffenberger, S, Babyev, J, Maurer, G, Mascherbauer, J, Kockova, R, Tintera, J, Kautznerova, D, Cerna, D, Sedlacek, K, Kryze, L, El-Husseini, W, Sikula, V, Segetova, M, Kautzner, J, Vasconcelos, M, Lebreiro, A, Martins, E, Cardoso, JS, Madureira, AJ, Ramos, I, Maciel, MJ, Florian, A, Ludwig, A, Rösch, S, Sechtem, U, Yilmaz, A, Monmeneu, J.V, López-Lereu, M.P, Bonanad, C, Sanchis, J, Chaustre, F, Merlos, P, Valero, E, Bodí, V, Chorro, F.J, Yalin, K, Golcuk, E, Ozer, CS, Buyukbayrak, H, Yilmaz, R, Dursun, M, Bilge, AK, Adalet, K, Klug, G, Reinstadler, SJ, Feistritzer, HJ, Mayr, A, Riegler, N, Schocke, M, Esterhammer, R, Kremser, C, Pachinger, O, Metzler, B, Siddiqi, N, Cameron, D, Neil, C, Jagpal, B, Singh, S, Schwarz, K, Papadopoulou, S, Frenneaux, MP, Dawson, D, Robbers, LFHJ, Eerenberg, ES, Teunissen, PFA, Jansen, MF, Hollander, MR, Horrevoets, AJG, Knaapen, P, Nijveldt, R, Levi, MM, van Rossum, AC, Niessen, HWM, Marcu, CB, Beek, AM, van Royen, N, Everaars, H, Robbers, LFHJ, Nijveldt, R, Beek, AM, Teunissen, PFA, Hirsch, A, van Royen, N, Zijlstra, F, Piek, JJ, van Rossum, AC, Goitein, O, Grupper, A, Hamdan, A, Eshet, Y, Beigel, R, Medvedofsky, D, Herscovici, R, Konen, E, Hod, H, Matetzky, S, Cadenas, R, Iniesta, AM, Refoyo, E, Antorrena, I, Guzman, G, Cuesta, E, Salvador, O, López, T, Moreno, M, López-Sendon, JL, Alam, SR, Spath, N, Richards, J, Dweck, M, Shah, A, Lang, N, Semple, S, MacGillivray, T, Mckillop, G, Mirsadraee, S, Pessotto, R, Zamvar, V, Newby, DE, Henriksen, P, Reiter, G, Reiter, U, Kovacs, G, Olschewski, H, Fuchsjäger, M, Ahmad, S, Raza, U, Malik, A, Sun, JP, Eisner, R, Mazur, W, ODonnell, R, Positano, V, Meloni, A, Santarelli, MF, Landini, L, Tassi, C, Grimaldi, S, Gulino, L, De Marchi, D, Chiodi, E, Renne, S, Lombardi, M, Pepe, A, Wu, L, Germans, T, Güçlü, A, Allaart, CP, van Rossum, AC, Kalisz, K, Lehenbauer, K, Katz, D, Bi, X, Cordts, M, Guetter, C, Jolly, M-P, Freed, B, Shah, S, Markl, M, Flukiger, J, Carr, J, Collins, J, Osiak, A, Tyrankiewicz, U, Jablonska, M, Jasinski, K, Jochym, PT, Chlopicki), S, Skorka, T, Kalisz, K, Semaan, E, Katz, D, Bi, X, Cordts, M, Guetter, C, Jolly, MP, Freed, B, Flukiger, J, Lee, D, Kansal, P, Shah, S, Markl, M, Carr, J, Collins, J, Groarke, JD, Shah, RV, Waller, AH, Abbasi, SA, Kwong, RY, Blankstein, R, Steigner, M, Chin, CWL, Semple, S, Malley, T, White, A, Prasad, S, Newby, DE, Dweck, M, Pepe, A, Meloni, A, Lai, ME, Vaquer, S, Gulino, L, De Marchi, D, Cuccia, L, Midiri, M, Vallone, A, Positano, V, Lombardi, M, Pedrotti, P, Milazzo, A, Quattrocchi, G, Roghi, A, Rimoldi, O, Barison, A, De Marchi, D, Masci, P, Milanesi, M, Aquaro, GD, Keilberg, P, Positano, V, Lombardi, M, Positano, Vincenzo, Barison, Andrea, Pugliese, Nicola Riccardo, Masci, Piergiorgio, Del Franco, Annamaria, Aquaro, Giovanni Donato, Landini, Luigi, Lombardi, Massimo, Dieringer, MA, Deimling, M, Fuchs, K, Winter, L, Kraus, O, Knobelsdorff-Brenkenhoff, FV, Schulz-Menger, J, Niendorf, T, Hinojar, R, Ucar, EA, DCruz, D, Sangle, S, Dabir, D, Voigt, T, Gaddum, N, Schaeffter, T, Nagel, E, Puntmann, VO, Sung, YM, Pontone, G, Andreini, D, Bertella, E, Mushtaq, S, Gripari, P, Cortinovis, S, Loguercio, M, Baggiano, A, Conte, E, Pepi, M, El ghannudi, S, Hop, O, Germain, P, Jeung, M-J, De Cesare, A, Roy, C, Gangi, A, Barone-Rochette, G, Pierard, S, Seldrum, S, De Meester de Ravensteen, C, Melchior, J, Maes, F, Pouleur, A-C, Vancraeynest, D, Pasquet, A, Vanoverschelde, J-L, L Gerber, B, Bekele, S, Singh, A, Khan, JN, Nazir, SA, Kanagala, P, McCann, GP, Singh, A, Steadman, CD, Bekele, S, Khan, JN, Nazir, SA, Kanagala, P, McCann, GP, Paelinck, BP, Vandendriessche, T, De Bock, D, De Maeyer, C, Parizel, PM, Christiaan, J, Trauzeddel, RF, Gelsinger, C, Butter, C, Barker, A, Markl, M, Schulz-Menger, J, von Knobelsdorff, F, Florian, A, Schäufele, T, Ludwig, A, Rösch, S, Wenzelburger, I, Yilmaz, A, Sechtem, U, López-Lereu, M.P, Bonanad, C, Monmeneu, J.V, Sanchís, J, Estornell, J, Igual, B, Maceira, A, Chorro, F.J, Focardi, M, Cameli, M, Bennati, E, Massoni, A, Solari, M, Carbone, F, Banchi, B, Mondillo, S, Miia, H, Kirsi, L, Helena, H, Tiina, H, Jyri, L, Pauli, P, Sari, K, Schumm, J, Greulich, S, Grün, S, Ong, P, Klingel, K, Kandolf, R, Sechtem, U, Mahrholdt, H, Raimondi, F, Ou, P, Boudjemline, Y, Bajolle, F, Iserin, F, Bonnet, D, Collins, J, Kalisz, K, Benefield, B, Sarnari, R, Katz, D, Bi, X, Cordts, M, Guetter, C, Jolly, M-P, Freed, B, Flukiger, J, Kansal, P, Lee, D, Shah, S, Markl, M, Carr, J, Sokolowska, B, Miszalski-Jamka, T, Szczeklik, W, Karwat, K, Miszalski-Jamka, K, Belzak, K, Mazur, W, Kereiakes, DJ, Jazwiec, P, Musial, J, Silva, G, Almeida, AG, Resende, C, Marques, JS, Silva, D, David, C, Amaro, C, Costa, P, Silva, JAP, Diogo, AN, Tsokolov, AV, Senchilo, VG, Vertelkin, AV, Hoffmann, P, Mykjåland, G, Wangberg, H, Tønnessen, T, Sjaastad, I, Nordsletten, L, Hjørnholm, U, Løset, A, Rostrup, M, Meloni, A, Gulino, L, Keilberg, P, Palazzi, G, Maddaloni, D, Ascioti, C, Missere, M, Salvatori, C, Positano, V, Lombardi, M, Pepe, A, Meloni, A, Filosa, A, Gulino, L, Pulini, S, Salvatori, C, Chiodi, E, Ascioti, C, Keilberg, P, Positano, V, Lombardi, M, Pepe, A, Meloni, A, Gulino, L, Pietrapertosa, A, Izzi, G, De Marchi, D, Valeri, G, Preziosi, P, Positano, V, Lombardi, M, Pepe, A, Meloni, A, Ruffo, GB, Keilberg, P, Gulino, L, Gerardi, C, Sallustio, G, Tudisca, C, Positano, V, Lombardi, M, Pepe, A, Greulich, S, Backes, M, Schumm, J, Grün, S, Sechtem, U, Mahrholdt, H, Dorniak, K, MSc, AS, Szurowska, E, Fijalkowski, M, Rawicz-Zegrzda, D, Dudziak, M, Raczak, G, Hamdan, A, Baker, FA, Klein, M, Di Segni, E, Goitein, O, Fibisch, G, Konen, E, Müller-Bierl, B, Tanaka, K, Buls, N, Fierens, Y, van Cauteren, T, Willekens, I, van Laere, S, Luypaert, R, de Mey, J, Muzzarelli, S, Faragasso, E, Pedrazzini, G, Sürder, D, Pasotti, E, Moccetti, T, Faletra, F, Qayyum, AA, Hasbak, P, Larsson, HB, Mathiasen, AB, Vejlstrup, NG, Kjaer, A, Kastrup, J, Moschetti, K, Favre, D, Pinget, C, Pilz, G, Petersen, S, Wagner, A, Wasserfallen, JB, Schwitter, J, Ghosh Dastidar, A, Cengarle, M, McAlindon, E, Augustine, D, Nightingale, AK, Bucciarelli-Ducci, C, Dandekar, VK, Ertel, AW, Dickens, C, Gonzalez, RC, Farzaneh-Far, A, Ripley, DP, Higgins, D, McDiarmid, AK, Bainbridge, GJ, Uddin, A, Kidambi, A, Herzog, B, Greenwood, JP, Plein, S, Khanji, M, Newton, T, Westwood, M, Sekhri, N, and Petersen, SE
- Abstract
Background-Aims: Early post-infarction pericardial injury is a common finding but its diagnosis remains elusive. Though C-reactive protein (CRP) is considered a marker of myocardial damage, reflecting myocardial inflammation at the infarcted area, we sought to assess the relationship between CRP and pericardial injury depicted by cardiovascular magnetic resonance (CMR) imaging in patients with ST elevation myocardial infarction (MI). Methods and results: 181 MI patients (84% male) were studied with CMR in the first week and at 4 months post-infarction to assess infarct characteristics, left ventricular volumes/function and pericardial injury. The latter was defined as pericardial fluid >4mm and/or enhancement on late gadolinium enhancement CMR. The CRP-value at day 2 (according to previous literature) was used for correlation with CMR and clinical parameters. Pericardial injury was noted in 87 patients, i.e. effusion (n = 30), inflammation (n = 46), both (n = 11). Patients with pericardial injury had significantly higher peak values of cardiac biomarkers (p<0.001) and higher peak CRP-values than patients with normal pericardium (median 13 vs 43 mg/dl, p<0.001). A strong correlation was found between peak CRP-values and a) left venticular ejection fraction and infarct size both at 1 week and 4 months, b) myocardial hemorrhage, microvascular obstruction (MVO) and pericardial injury at 1 week, c) cardiac biomarkers values and time to PCI. However in a multiple regression model only pericardial injury (p = 0.003) and less importantly time to PCI (p = 0.022) were the independent predictors of CRP values. Conclusion: Pericardial damage described by cardiac MRI occurs often after acute ST elevation MI. CRP-values at the acute phase of MI reflect not only inflammation at the infarcted area but even more the inflammation of the surrounding pericardial tissue.
Table 1 Comparison of baseline clinical and biochemical parameters of patients with or without evidence of early post-infarct pericardial damage on CMR Normal Group (n = 94) Pericardial injury group (n = 87) p-value Agem, years 59±11 60±12 0.48 Male, n(%) 83 (88) 69 (79) 0.10 Diabets, n(%) 12 (13) 9 (10) 0.61 Smoker, n(%) 52 (55) 44 (51) 0.52 Hyperlipidemia, n(%) 56 (60) 55 (63) 0.62 BSA m2 2.0 ± 0.2 2.0 ± 0.2 0.20 Time to PCI, min 195 (155 − 274) 223 (160 − 335) 0.20 Troponin I, μ/l 44 (19 − 92) 90 (44 − 149) >0.001 CK-MB, U/L 128 (77 − 216) 250 (143 − 443) >0.001 CRP, mg/dL 13 (7 − 28) 43 (16 − 96) >0.001 Day of peak CRP 2 (1 − 3) 2 (1 − 3) 0.39 Table 2 Significant correlations between CRP Values and corresponding CMR measurements, cardic biomarkers and clinical related parameters Varibles Spearmanscorrelations r p-value CMR parameters 1 week LV EF −0.28 >0,001 Infractsize(%ofLV) 0.40 >0,001 Microvasular obstruction 0.27 >0,001 Hemorrhage 0.33 >0,001 Size of area atrisk 0.31 >0,001 Transmurality 0.30 >0,001 Pericaldial damage 0.43 >0,001 CMR parameters 4 months LVEF −0.43 >0,001 Infarctsize(%ofLV) 0.46 >0,001 Cardiac Biomarkers Peak TnI 0.34 >0,001 Peak CK-MB 0.32 >0,001 Other Time to PCI 0,182 0,007 - Published
- 2013
- Full Text
- View/download PDF
3. Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
- Author
-
Marta Consegal, Ignasi Barba, Bruno García del Blanco, Imanol Otaegui, José F. Rodríguez-Palomares, Gerard Martí, Bernat Serra, Neus Bellera, Manuel Ojeda-Ramos, Filipa Valente, Maria Ángeles Carmona, Elisabet Miró-Casas, Antonia Sambola, Rosa María Lidón, Jordi Bañeras, José Antonio Barrabés, Cristina Rodríguez, Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Barba I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Faculty of Medicine, University of Vic - Central University of Catalonia (UVicUCC), Vic, Spain. [García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Valente F, Carmona MÁ, Miró-Casas E, Sambola A, Lidón RM, Bañeras J, Barrabés JA] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, CIBERESP, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Reperfusion [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Infart de miocardi ,Multidisciplinary ,Reperfusió (Fisiologia) ,compuestos orgánicos::ácidos carboxílicos::ácidos acíclicos::ácidos dicarboxílicos::succinatos::ácido succínico [COMPUESTOS QUÍMICOS Y DROGAS] ,Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Dicarboxylic Acids::Succinates::Succinic Acid [CHEMICALS AND DRUGS] ,intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::reperfusión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] - Abstract
Cardiovascular biology; Diagnostic markers; Prognostic markers Biología cardiovascular; Marcadores de diagnóstico; Marcadores pronósticos Biologia cardiovascular; Marcadors diagnòstics; Marcadors pronòstics Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by 1H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p
- Published
- 2023
4. Fully Three-Dimensional Hemodynamic Characterization of Altered Blood Flow in Bicuspid Aortic Valve Patients With Respect to Aortic Dilatation: A Finite Element Approach
- Author
-
Julio Sotelo, Pamela Franco, Andrea Guala, Lydia Dux-Santoy, Aroa Ruiz-Muñoz, Arturo Evangelista, Hernan Mella, Joaquín Mura, Daniel E. Hurtado, José F. Rodríguez-Palomares, Sergio Uribe, Institut Català de la Salut, [Sotelo J] School of Biomedical Engineering, Universidad de Valparaíso, Valparaíso, Chile. Biomedical Imaging Center, Pontificia Universidad Católica de Chile, Santiago, Chile. Millennium Institute for Intelligent Healthcare Engineering, iHEALTH, Santiago, Chile. Millennium Nucleus in Cardiovascular Magnetic Resonance, Cardio MR, Santiago, Chile. [Franco P] Biomedical Imaging Center, Pontificia Universidad Católica de Chile, Santiago, Chile. Millennium Institute for Intelligent Healthcare Engineering, iHEALTH, Santiago, Chile. Millennium Nucleus in Cardiovascular Magnetic Resonance, Cardio MR, Santiago, Chile. Department of Electrical Engineering, Pontificia Universidad Católica de Chile, Santiago, Chile. [Guala A, Dux-Santoy L, Ruiz-Muñoz A, Evangelista A, Rodríguez-Palomares JF] Servei de Cardiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Pathological Conditions, Signs and Symptoms::Pathological Conditions, Anatomical::Dilatation, Pathologic [DISEASES] ,Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics [PHENOMENA AND PROCESSES] ,Cor - Vàlvules - Malalties - Imatgeria ,fenómenos fisiológicos respiratorios y circulatorios::fenómenos fisiológicos cardiovasculares::hemodinámica [FENÓMENOS Y PROCESOS] ,Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases [DISEASES] ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,afecciones patológicas, signos y síntomas::afecciones patológicas anatómicas::dilatación patológica [ENFERMEDADES] ,Aneurismes aòrtics ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades de las válvulas cardíacas [ENFERMEDADES] ,Cardiology and Cardiovascular Medicine ,Monitoratge hemodinàmic ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] - Abstract
Bicuspid aortic valve; Congenital heart disease; Magnetic resonance imaging Vàlvula aòrtica bicúspide; Cardiopatia congènita; Imatges per ressonància magnètica Válvula aórtica bicúspide; Cardiopatía congénita; Imágenes de resonancia magnética Background and Purpose: Prognostic models based on cardiovascular hemodynamic parameters may bring new information for an early assessment of patients with bicuspid aortic valve (BAV), playing a key role in reducing the long-term risk of cardiovascular events. This work quantifies several three-dimensional hemodynamic parameters in different patients with BAV and ranks their relationships with aortic diameter. Materials and Methods: Using 4D-flow CMR data of 74 patients with BAV (49 right-left and 25 right-non-coronary) and 48 healthy volunteers, aortic 3D maps of seventeen 17 different hemodynamic parameters were quantified along the thoracic aorta. Patients with BAV were divided into two morphotype categories, BAV-Non-AAoD (where we include 18 non-dilated patients and 7 root-dilated patients) and BAV-AAoD (where we include the 49 patients with dilatation of the ascending aorta). Differences between volunteers and patients were evaluated using MANOVA with Pillai's trace statistic, Mann–Whitney U test, ROC curves, and minimum redundancy maximum relevance algorithm. Spearman's correlation was used to correlate the dilation with each hemodynamic parameter. Results: The flow eccentricity, backward velocity, velocity angle, regurgitation fraction, circumferential wall shear stress, axial vorticity, and axial circulation allowed to discriminate between volunteers and patients with BAV, even in the absence of dilation. In patients with BAV, the diameter presented a strong correlation (> |+/−0.7|) with the forward velocity and velocity angle, and a good correlation (> |+/−0.5|) with regurgitation fraction, wall shear stress, wall shear stress axial, and vorticity, also for morphotypes and phenotypes, some of them are correlated with the diameter. The velocity angle proved to be an excellent biomarker in the differentiation between volunteers and patients with BAV, BAV morphotypes, and BAV phenotypes, with an area under the curve bigger than 0.90, and higher predictor important scores. Conclusions: Through the application of a novel 3D quantification method, hemodynamic parameters related to flow direction, such as flow eccentricity, velocity angle, and regurgitation fraction, presented the best relationships with a local diameter and effectively differentiated patients with BAV from healthy volunteers. This work was funded by ANID – Millennium Science Initiative Program – ICN2021_004 and ANID – Millennium Science Initiative Program – NCN17_129, CONICYT-FONDECYT Postdoctorado #3170737, ANID – FONDECYT Postdoctorado #3220266, ANID Ph. D. Scholarship 21170592, ANID FONDECYT de Iniciación en Investigación #11200481, ANID FONDECYT #1181057, ANID Ph. D. Scholarship 21180391, the Spanish Society of Cardiology (SEC/FEC-INV-CLI 20/015) and the Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV). AG has received funding from the Spanish Ministry of Science, Innovation and Universities (IJC2018-037349-I).
- Published
- 2022
5. Multimodality Cardiac Imaging in Cardiomyopathies : From Diagnosis to Prognosis
- Author
-
Casas Masnou, Guillem, Rodríguez Palomares, Jose Fernando, Institut Català de la Salut, [Casas G, Rodríguez-Palomares JF] Unitat d’Ecocardiografia i Imatge Cardíaca, Unitat de Cardiopaties Hereditàries, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Left ventricular ejection fraction ,diagnosis ,Cardiomyopathy ,Miocardi - Malalties ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,left ventricular ejection fraction ,General Medicine ,Prognosis ,Late gadolinium enhancement ,Cardiovascular Diseases::Heart Diseases::Cardiomyopathies [DISEASES] ,late gadolinium enhancement ,enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías [ENFERMEDADES] ,Diagnosis ,Medicine ,prognosis ,Cor - Imatgeria ,cardiomyopathy ,Multimodality cardiac imaging techniques ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,multimodality cardiac imaging techniques - Abstract
Cardiomyopathy; Diagnosis; Prognosis Miocardiopatía; Diagnóstico; Pronóstico Miocardiopatia; Diagnòstic; Pronòstic Cardiomyopathies are a group of structural and/or functional myocardial disorders which encompasses hypertrophic, dilated, arrhythmogenic, restrictive, and other cardiomyopathies. Multimodality cardiac imaging techniques are the cornerstone of cardiomyopathy diagnosis; transthoracic echocardiography should be the first-line imaging modality due to its availability, and diagnosis should be confirmed by cardiovascular magnetic resonance, which will provide more accurate morphologic and functional information, as well as extensive tissue characterization. Multimodality cardiac imaging techniques are also essential in assessing the prognosis of patients with cardiomyopathies; left ventricular ejection fraction and late gadolinium enhancement are two of the main variables used for risk stratification, and they are incorporated into clinical practice guidelines. Finally, periodic testing with cardiac imaging techniques should also be performed due to the evolving and progressive natural history of most cardiomyopathies.
- Published
- 2022
6. Intraventricular Conundrum in a SARS-CoV-2-Positive Patient With Elevated Biomarkers of Myocardial Injury
- Author
-
Servato, María L., Valente, Filipa, García-Moreno, Laura Gutiérrez, Casas, Guillem, Fernández-Galera, Ruben, Burcet, Gemma, Teixidó-Tura, Gisela, Calabria, Hug Cuéllar, González, Ignacio Ferreira, Rodríguez-Palomares, José F., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Servato ML, Valente FX, García-Moreno LG, Casas G, Fernández-Galera R, Teixidó-Tura G, Rodríguez-Palomares JF] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Center for Biomedical Investigation Cardiovascular Consortium, Madrid, Spain. [Burcet G, Calabria HC] Servei de Radiologia, Institut d’Imatge per al Diagnòstic, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [González IF] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Center for Biomedical Investigation Epidemiology and Public Health Consortium, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,viruses ,enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías::miocarditis [ENFERMEDADES] ,Case Report ,030105 genetics & heredity ,COVID-19 (Malaltia) ,0302 clinical medicine ,CMR, cardiac magnetic resonance ,LVEF, left ventricular ejection fraction ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Medicine ,echocardiography ,Fio2, fraction of inspired oxygen ,Computed tomography ,Pneumònia vírica ,COVID-19, coronavirus disease-2019 ,NT-proBNP, N-terminal pro-B-type natriuretic peptide ,SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2 ,virus diseases ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,enfermedades respiratorias::enfermedades respiratorias::infecciones del tracto respiratorio::neumonía::neumonía vírica [ENFERMEDADES] ,Positive patient ,Thrombosis ,Fi, fraction of inspired oxygen ,Myocarditis ,thrombus ,Echocardiography ,Cardiology ,cardiovascular system ,Cardiology and Cardiovascular Medicine ,cardiovascular magnetic resonance (CMR) ,Thrombus ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Other subheadings::Other subheadings::Other subheadings::/virology [Other subheadings] ,Miocarditis - Tractament ,03 medical and health sciences ,Clinical Case ,Internal medicine ,Diseases of the circulatory (Cardiovascular) system ,cardiovascular diseases ,LV, left ventricular ,Otros calificadores::Otros calificadores::Otros calificadores::/virología [Otros calificadores] ,business.industry ,COVID-19 ,computed tomography ,medicine.disease ,Atypical pneumonia ,RC666-701 ,Heart failure ,NT-proBNP, N-terminal pro–B-type natriuretic peptide ,myocarditis ,Respiratory Tract Diseases::Respiratory Tract Diseases::Respiratory Tract Infections::Pneumonia::Pneumonia, Viral [DISEASES] ,business ,Cardiovascular Diseases::Heart Diseases::Cardiomyopathies::Myocarditis [DISEASES] ,030217 neurology & neurosurgery ,Cardiovascular magnetic resonance (CMR) - Abstract
We present a case of acute myocarditis with left ventricular dysfunction and intracavitary thrombosis in a 55-year-old man with severe acute respiratory syndrome coronavirus 2 infection (coronavirus disease 2019) who was admitted with bilateral atypical pneumonia. The patient was treated with anticoagulation and optimal heart failure therapy and had an improvement of left ventricular function and thrombus resolution. (Level of Difficulty: Intermediate.), Graphical abstract
- Published
- 2021
7. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction
- Author
-
Jordi Bañeras, Filipa Valente, Ignacio Ferreira-González, Imanol Otaegui, Ana Sánchez, Laura Castellote, Begoña Benito, Agnès Rafecas, José A. Barrabés, Javier Inserte, José Rodríguez-Palomares, Antonio Rodríguez-Sinovas, Victor Pineda, Elisabet Miró-Casas, Sara Delgado-Tomas, David Beneítez, Rosa-Maria Lidón, Irene Buera, Laia Milà, Antonia Sambola, David Aluja, Marisol Ruiz-Meana, Institut Català de la Salut, [Inserte J, Barrabés JA, Aluja D, Otaegui I, Bañeras J, Sánchez A, Rodríguez-Palomares JF, Miró-Casas E, Milà L, Lidón RM, Sambola A, Valente F, Rafecas A, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Buera I, Delgado-Tomás S, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Castellote L] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Beneítez D] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_treatment ,myocardial reperfusion ,intervenciones quirúrgicas::intervenciones quirúrgicas::procedimientos quirúrgicos mínimamente invasivos::procedimientos endovasculares::cirugía coronaria percutánea [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,iron deficiency ,CMR, cardiac magnetic resonance ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica [ENFERMEDADES] ,ID, iron deficiency ,Myocardial infarction ,sGC, soluble guanylyl cyclase ,Malalties coronàries - Cirurgia - Complicacions ,medicine.diagnostic_test ,CK-MB, creatine kinase-myocardial band ,eNOS, endothelial nitric oxide synthase ,Iron deficiency ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Surgical Procedures, Operative::Surgical Procedures, Operative::Minimally Invasive Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Sgc, soluble guanylyl cyclase ,Cardiology ,cardiovascular system ,iNOS, inducible nitric oxide synthase ,Infart de miocardi - Imatgeria ,Cardiology and Cardiovascular Medicine ,STEMI, ST-segment elevation acute myocardial infarction ,soluble guanylate cyclase ,medicine.medical_specialty ,Ischemia ,acute myocardial infarction ,Acute myocardial infarction ,MVO, microvascular obstruction ,Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency [DISEASES] ,Myocardial reperfusion ,Enos, endothelial nitric oxide synthase ,Cardiac magnetic resonance imaging ,Clinical Research ,Internal medicine ,STIR, short tau inversion recovery ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,medicine ,Soluble guanylate cyclase ,HSP90, heat-shock protein 90 ,cardiovascular diseases ,Ventricular remodeling ,LV, left ventricular ,endothelial nitric oxide synthase ,Dèficit de ferro ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,Coronary occlusion ,Inos, inducible nitric oxide synthase ,PKG, protein kinase G ,Endothelial nitric oxide synthase ,business ,cGMP-dependent protein kinase ,VASP, vasodilator-stimulated phosphoprotein - Abstract
Visual Abstract, Highlights • In patients with STEMI treated with primary percutaneous coronary intervention, iron deficiency is associated with larger infarcts, more extensive microvascular obstruction, and a higher frequency of adverse left ventricular remodeling. • An iron-deficient diet reduces the tolerance to ischemia/reperfusion in mice at least in part by interfering with the cardioprotective pathway eNOS/soluble guanylate cyclase/protein kinase G. • An iron-deficient diet reduces eNOS activity by increasing oxidative/nitrosative stress and its proteasome-dependent degradation. • Not only iron excess but also iron deficiency may have deleterious effects in the context of acute myocardial ischemia., Summary In patients with a first anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention, iron deficiency (ID) was associated with larger infarcts, more extensive microvascular obstruction, and higher frequency of adverse left ventricular remodeling as assessed by cardiac magnetic resonance imaging. In mice, an ID diet reduced the activity of the endothelial nitric oxide synthase/soluble guanylate cyclase/protein kinase G pathway in association with oxidative/nitrosative stress and increased infarct size after transient coronary occlusion. Iron supplementation or administration of an sGC activator before ischemia prevented the effects of the ID diet in mice. Not only iron excess, but also ID, may have deleterious effects in the setting of ischemia and reperfusion.
- Published
- 2021
8. Radiomics-Based Classification of Left Ventricular Non-compaction, Hypertrophic Cardiomyopathy, and Dilated Cardiomyopathy in Cardiovascular Magnetic Resonance
- Author
-
Cristian Izquierdo, Guillem Casas, Carlos Martin-Isla, Victor M. Campello, Andrea Guala, Polyxeni Gkontra, Jose F. Rodríguez-Palomares, Karim Lekadir, Institut Català de la Salut, [Izquierdo C, Martin-Isla C, Campello VM, Gkontra P] Artificial Intelligence in Medicine Lab (BCN-AIM), Departament de Matemàtiques i Informàtica, Universitat de Barcelona, Barcelona, Spain. [Casas G, Rodríguez-Palomares JF] Servei de Cardiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Guala A] Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_specialty ,Heart diseases ,Local binary patterns ,Cardiomyopathy ,Cardiovascular Medicine ,Malalties del cor ,Radiomics ,Internal medicine ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Aprenentatge automàtic ,Machine learning ,medicine ,Diseases of the circulatory (Cardiovascular) system ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,cardiovascular diseases ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Original Research ,enfermedades cardiovasculares [ENFERMEDADES] ,medicine.diagnostic_test ,Cardiovascular Diseases [DISEASES] ,business.industry ,Sistema cardiovascular - Malalties - Imatgeria per ressonància magnètica ,Hypertrophic cardiomyopathy ,Dilated cardiomyopathy ,Magnetic resonance imaging ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,medicine.disease ,hypertrophic cardiomyopathy ,dilated cardiomyopathy ,Diagnòstic per la imatge ,machine learning ,radiomics ,RC666-701 ,Cardiology ,cardiovascular system ,left-ventricle non-compaction ,Diagnostic imaging ,Sistema cardiovascular - Malalties - Diagnòstic ,Differential diagnosis ,Cardiology and Cardiovascular Medicine ,business ,Electrocardiography - Abstract
Miocardiopatía dilatada; Miocardiopatía hipertrófica; Radiómica Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Radiomics Miocardiopatia dilatada; Miocardiopatia hipertròfica; Radiòmica Left Ventricular (LV) Non-compaction (LVNC), Hypertrophic Cardiomyopathy (HCM), and Dilated Cardiomyopathy (DCM) share morphological and functional traits that increase the diagnosis complexity. Additional clinical information, besides imaging data such as cardiovascular magnetic resonance (CMR), is usually required to reach a definitive diagnosis, including electrocardiography (ECG), family history, and genetics. Alternatively, indices of hypertrabeculation have been introduced, but they require tedious and time-consuming delineations of the trabeculae on the CMR images. In this paper, we propose a radiomics approach to automatically encode differences in the underlying shape, gray-scale and textural information in the myocardium and its trabeculae, which may enhance the capacity to differentiate between these overlapping conditions. A total of 118 subjects, including 35 patients with LVNC, 25 with HCM, 37 with DCM, as well as 21 healthy volunteers (NOR), underwent CMR imaging. A comprehensive radiomics characterization was applied to LV short-axis images to quantify shape, first-order, co-occurrence matrix, run-length matrix, and local binary patterns. Conventional CMR indices (LV volumes, mass, wall thickness, LV ejection fraction—LVEF—), as well as hypertrabeculation indices by Petersen and Jacquier, were also analyzed. State-of-the-art Machine Learning (ML) models (one-vs.-rest Support Vector Machine—SVM—, Logistic Regression—LR—, and Random Forest Classifier—RF—) were used for one-vs.-rest classification tasks. The use of radiomics models for the automated diagnosis of LVNC, HCM, and DCM resulted in excellent one-vs.-rest ROC-AUC values of 0.95 while generating these results without the need for the delineation of the trabeculae. First-order and texture features resulted to be among the most discriminative features in the obtained radiomics signatures, indicating their added value for quantifying relevant tissue patterns in cardiomyopathy differential diagnosis. This publication was partially funded by the European Union's Horizon 2020 research and innovation euCanSHare project under grant agreement No 825903. KL received funding from the Spanish Ministry of Science, Innovation and Universities under grant agreement RTI2018-099898-B-I00. AG has received funding from the Spanish Ministry of Science, Innovation and Universities (IJC2018-037349-I).
- Full Text
- View/download PDF
9. Prediction of left ventricular thrombus after myocardial infarction: a cardiac magnetic resonance-based prospective registry.
- Author
-
Bertolin-Boronat C, Marcos-Garcés V, Merenciano-González H, Perez N, Pérez Del Villar C, Gavara J, Lopez-Lereu MP, Monmeneu JV, Herrera Flores C, Domenech-Ximenos B, López-Fornás FJ, Rios-Navarro C, de Dios E, Moratal D, Ortiz-Pérez JT, Bayes-Genis A, Rodríguez-Palomares JF, Nuñez J, Sánchez PL, Sanchis J, and Bodi V
- Abstract
Background: Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI)., Objectives: We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission., Methods: We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction., Results: LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in ≥1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated., Conclusions: LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection., Competing Interests: Conflict of interest disclosures Julio Núñez reports personal fees from Alleviant, Bayer, Astra Zeneca, Novartis, Boehringer-Ingelheim, Rovi, and Novo Nordisk, not related to the contents of this paper. The other authors report no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Mitral Transcatheter Edge-to-Edge Repair and Clinical Value of Novel Echocardiographic Biomarkers: A Hypothesis-Generating Study.
- Author
-
Solsona-Caravaca J, Fernández-Galera R, González-Fernández V, Airale L, Rivas J, Scudeler L, Vallejo N, Teixidó-Turà G, Casas G, Valente F, Oliveró R, Belahnech Y, Martí G, García B, Ferreira-González I, Rodríguez-Palomares JF, and Galian-Gay L
- Abstract
Background: Longitudinal data on reverse cardiac remodeling and outcomes after transcatheter edge-to-edge repair (TEER) are limited., Methods: A total of 78 patients with severe mitral regurgitation (MR) were included retrospectively. All patients had echocardiography at baseline and again six months after TEER. They were monitored for a primary composite endpoint, consisting of heart failure hospitalization and cardiovascular death, over 13 months., Results: Significant decreases in the left ventricular ejection fraction (LVEF), all myocardial work indices (except global wasted work), and the left atrial reservoir were observed after TEER. Additionally, there was a decrease in the pulmonary artery systolic pressure and an increase in the tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio. A post-TEER TAPSE/PASP ratio of <0.47 (HR: 4.76, p -value = 0.039), and a post-TEER left atrial reservoir of <9.0% (HR: 2.77, p -value = 0.047) were associated with the primary endpoint., Conclusions: Echocardiography post-TEER reflects impairment in ventricular performance due to preload reduction and right ventricle and pulmonary artery coupling improvement. Short-term echocardiography after TEER identifies high-risk patients who could benefit from a close clinical follow-up. The prognostic significance of LA strain and the TAPSE/PASP ratio should be validated in subsequent large-scale prospective studies.
- Published
- 2024
- Full Text
- View/download PDF
11. European Association of Cardiovascular Imaging survey on cardiovascular multimodality imaging in acute myocarditis.
- Author
-
Bohbot Y, Pezel T, Demirkıran A, Androulakis E, Houshmand G, Szabo L, Manka R, Botezatu SB, Rodríguez-Palomares JF, Biering-Sørensen T, Podlesnikar T, and Dweck MR
- Subjects
- Humans, Male, Female, Europe, Acute Disease, Magnetic Resonance Imaging, Cine methods, Computed Tomography Angiography, Adult, Echocardiography, Middle Aged, Societies, Medical, Surveys and Questionnaires, Coronary Angiography, Myocarditis diagnostic imaging, Multimodal Imaging
- Abstract
Aims: To assess the current role of cardiac imaging in the diagnosis, management, and follow-up of patients with acute myocarditis (AM) through a European Association of Cardiovascular Imaging survey., Methods and Results: A total of 412 volunteers from 74 countries responded to the survey. Most participants worked in tertiary centres (56%). All participants had access to echocardiography, while 79 and 75% had access to cardiac computed tomography angiography (CCTA) and cardiac magnetic resonance (CMR), respectively. Less than half (47%) had access to myocardial biopsy, and only 5% used this test routinely. CMR was performed within 7 days of presentation in 73% of cases. Non-ischaemic late gadolinium enhancement (LGE, 88%) and high-signal intensity in T2-weighted images (74%) were the most used diagnostic criteria for AM. CCTA was preferred to coronary angiography by 47% of participants to exclude coronary artery disease. Systematic prescription of beta-blockers and angiotensin-converting enzyme inhibitors was reported by 38 and 32% of participants. Around a quarter of participants declared considering LGE burden as a reason to treat. Most participants (90%) reported performing a follow-up echocardiogram, while 63% scheduled a follow-up CMR. The main reason for treatment discontinuation was improvement of left ventricular ejection fraction (89%), followed by LGE regression (60%). In two-thirds of participants, the decision to resume high-intensity sport was influenced by residual LGE., Conclusion: This survey confirms the high utilization of cardiac imaging in AM but reveals major differences in how cardiac imaging is used and how the condition is managed between centres, underlining the need for recommendation statements in this topic., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
12. Rare Genetic Variants in Young Adults Requiring Pacemaker Implantation.
- Author
-
Ochoa JP, Espinosa MÁ, Gayan-Ordas J, Fernández-Valledor A, Gallego-Delgado M, Tirón C, Lozano-Ibañez A, García-Pinilla JM, Rodríguez-Palomares JF, Larrañaga-Moreira JM, Llamas-Gómez H, Ripoll-Vera T, Braza-Boïls A, Vilches S, Méndez I, Bascompte-Claret R, García-Álvarez A, Villacorta E, Fernandez-Lozano I, Lara-Pezzi E, and Garcia-Pavia P
- Abstract
Background: Genetic disease has recently emerged as a cause of cardiac conduction disorders (CCDs), but the diagnostic yield of genetic testing and the contribution of the different genes to CCD is still unsettled., Objectives: This study sought to determine the diagnostic yield of genetic testing in young adults with CCD of unknown etiology requiring pacemaker implantation. We also studied the prevalence of rare protein-altering variants across individual genes and functional gene groups., Methods: We performed whole exome sequencing in 150 patients with CCD of unknown etiology who had permanent pacemaker implanted at age ≤60 years at 14 Spanish hospitals. Prevalence of rare protein-altering variants in patients with CCD was compared with a reference population of 115,522 individuals from gnomAD database (control subjects)., Results: Among 39 prioritized genes, patients with CCD had more rare protein-altering variants than control subjects (OR: 2.39; 95% CI: 1.75-3.33). Significant enrichment of rare variants in patients with CCD was observed in all functional gene groups except in the desmosomal genes group. Rare variants in the nuclear envelope genes group exhibited the strongest association with CCD (OR: 6.77; 95% CI: 3.71-13.87). Of note, rare variants in sarcomeric genes were also enriched (OR: 1.73; 95% CI: 1.05-3.10). An actionable genetic variant was detected in 21 patients (14%), with LMNA being the most frequently involved gene (4.6%)., Conclusions: Unrecognized rare genetic variants increase the risk of CCD in young adults with CCD of unknown etiology. Genetic testing should be performed in patients age ≤60 years with CCD of unknown etiology. The role of genetic variants in sarcomeric genes as a cause of CCD should be further investigated., Competing Interests: Funding Support and Author Disclosures This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI17/01941 and PI20/01379” (cofunded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future"). The CNIC is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). The Hospital Universitario Puerta de Hierro, the Hospital Gregorio Marañón, and the Vall Hebron Hospital are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart. Dr Ochoa is employee of Health in Code. Dr Braza-Boïls is supported by Marató TV3 (736/C/2020) and Health Research Institute La Fe. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial.
- Author
-
Evangelista A, Galian-Gay L, Guala A, Teixido-Tura G, Calvo-Iglesias F, Sevilla T, Bermejo J, Méndez I, Sánchez V, Robledo Carmona JM, Alegret JM, Ferrer-Sistach E, Saura D, Ruiz-Muñoz A, Dux-Santoy L, Carmona MÁ, Huguet M, Cuellar-Calabria H, Sao-Avilés A, Ferreira-González I, and Rodríguez-Palomares JF
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Dilatation, Pathologic drug therapy, Follow-Up Studies, Double-Blind Method, Treatment Outcome, Aorta diagnostic imaging, Aorta pathology, Aorta drug effects, Aortic Valve Disease drug therapy, Aortic Valve Stenosis, Atorvastatin therapeutic use, Aortic Valve diagnostic imaging, Aortic Valve pathology, Aortic Valve abnormalities, Aortic Valve drug effects, Disease Progression, Calcinosis drug therapy, Calcinosis diagnostic imaging, Calcinosis pathology, Bicuspid Aortic Valve Disease diagnostic imaging, Bicuspid Aortic Valve Disease drug therapy, Heart Valve Diseases drug therapy, Heart Valve Diseases diagnostic imaging, Heart Valve Diseases pathology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
- Abstract
Background: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification., Methods: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46±13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were ≥18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter ≤50 mm. Computed tomography and echocardiography studies were performed at baseline and after 3 years of treatment., Results: During follow-up, 28 patients (12.7%) discontinued medical treatment (15 on atorvastatin and 13 taking placebo). Thus, 192 patients completed the 36 months of treatment. Low-density lipoprotein cholesterol levels decreased significantly in the atorvastatin group (median [interquartile range], -30 mg/dL [-51.65 to -1.75 mg/dL] versus 6 mg/dL [-4, 22.5 mg/dL]; P <0.001). The maximum ascending aorta diameter increased with no differences between groups: 0.65 mm (95% CI, 0.45-0.85) in the atorvastatin group and 0.74 mm (95% CI, 0.45-1.04) in the placebo group ( P =0.613). Similarly, no significant differences were found for the progression of the aortic valve calcium score ( P =0.167) or valvular dysfunction., Conclusions: Among patients with bicuspid aortic valve without severe valvular dysfunction, atorvastatin treatment was not effective in reducing the progression of ascending aorta dilation and aortic valve calcification during 3 years of treatment despite a significant reduction in low-density lipoprotein cholesterol levels., Registration: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001808-57. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02679261., Competing Interests: Disclosures None.
- Published
- 2024
- Full Text
- View/download PDF
14. Cardiac resynchronization therapy with triple fusion using the SyncAV dynamic algorithm compared to conventionally optimized biventricular pacing: Results from the multicentric, randomized, double-blinded CRUSTY trial.
- Author
-
Francisco-Pascual J, Adeliño R, Quesada A, Sainz Godoy I, Exposito V, Ferrando J, Fernadez Armenta J, Cabanas P, Pérez-Rodon J, Santos-Ortega A, Villuendas R, Trucco E, Benito B, Jordan-Marchite P, Rodríguez-Palomares JF, Ferreira-González I, and Rivas-Gándara N
- Published
- 2024
- Full Text
- View/download PDF
15. Arrhythmic Mitral Valve Prolapse Phenotype: An Unsupervised Machine Learning Analysis Using a Multicenter Cardiac MRI Registry.
- Author
-
Akyea RK, Figliozzi S, Lopes PM, Bauer KB, Moura-Ferreira S, Tondi L, Mushtaq S, Censi S, Pavon AG, Bassi I, Galian-Gay L, Teske AJ, Biondi F, Filomena D, Stylianidis V, Torlasco C, Muraru D, Monney P, Quattrocchi G, Maestrini V, Agati L, Monti L, Pedrotti P, Vandenberk B, Squeri A, Lombardi M, Ferreira AM, Schwitter J, Aquaro GD, Pontone G, Chiribiri A, Rodríguez Palomares JF, Yilmaz A, Andreini D, Florian AR, Francone M, Leiner T, Abecasis J, Badano LP, Bogaert J, Georgiopoulos G, and Masci PG
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Registries, Magnetic Resonance Imaging, Cine methods, Arrhythmias, Cardiac diagnostic imaging, Arrhythmias, Cardiac physiopathology, Adult, Magnetic Resonance Imaging, Mitral Valve Prolapse diagnostic imaging, Unsupervised Machine Learning, Phenotype
- Abstract
Purpose To use unsupervised machine learning to identify phenotypic clusters with increased risk of arrhythmic mitral valve prolapse (MVP). Materials and Methods This retrospective study included patients with MVP without hemodynamically significant mitral regurgitation or left ventricular (LV) dysfunction undergoing late gadolinium enhancement (LGE) cardiac MRI between October 2007 and June 2020 in 15 European tertiary centers. The study end point was a composite of sustained ventricular tachycardia, (aborted) sudden cardiac death, or unexplained syncope. Unsupervised data-driven hierarchical k -mean algorithm was utilized to identify phenotypic clusters. The association between clusters and the study end point was assessed by Cox proportional hazards model. Results A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 female, 230 male) with two phenotypic clusters were identified. Patients in cluster 2 (199 of 474, 42%) had more severe mitral valve degeneration (ie, bileaflet MVP and leaflet displacement), left and right heart chamber remodeling, and myocardial fibrosis as assessed with LGE cardiac MRI than those in cluster 1. Demographic and clinical features (ie, symptoms, arrhythmias at Holter monitoring) had negligible contribution in differentiating the two clusters. Compared with cluster 1, the risk of developing the study end point over a median follow-up of 39 months was significantly higher in cluster 2 patients (hazard ratio: 3.79 [95% CI: 1.19, 12.12], P = .02) after adjustment for LGE extent. Conclusion Among patients with MVP without significant mitral regurgitation or LV dysfunction, unsupervised machine learning enabled the identification of two phenotypic clusters with distinct arrhythmic outcomes based primarily on cardiac MRI features. These results encourage the use of in-depth imaging-based phenotyping for implementing arrhythmic risk prediction in MVP. Keywords: MR Imaging, Cardiac, Cardiac MRI, Mitral Valve Prolapse, Cluster Analysis, Ventricular Arrhythmia, Sudden Cardiac Death, Unsupervised Machine Learning Supplemental material is available for this article. © RSNA, 2024.
- Published
- 2024
- Full Text
- View/download PDF
16. Three-dimensional aortic geometry mapping via registration of non-gated contrast-enhanced or gated and respiratory-navigated MR angiographies.
- Author
-
Dux-Santoy L, Rodríguez-Palomares JF, Teixidó-Turà G, Garrido-Oliver J, Carrasco-Poves A, Morales-Galán A, Ruiz-Muñoz A, Casas G, Valente F, Galian-Gay L, Fernández-Galera R, Oliveró R, Cuéllar-Calabria H, Roque A, Burcet G, Barrabés JA, Ferreira-González I, and Guala A
- Subjects
- Humans, Reproducibility of Results, Male, Female, Retrospective Studies, Middle Aged, Aged, Respiratory-Gated Imaging Techniques, Adult, Time Factors, Image Interpretation, Computer-Assisted, Cardiac-Gated Imaging Techniques, Predictive Value of Tests, Imaging, Three-Dimensional, Aorta, Thoracic diagnostic imaging, Magnetic Resonance Angiography, Observer Variation, Contrast Media administration & dosage, Aortic Diseases diagnostic imaging
- Abstract
Background: The measurement of aortic dimensions and their evolution are key in the management of patients with aortic diseases. Manual assessment, the current guideline-recommended method and clinical standard, is subjective, poorly reproducible, and time-consuming, limiting the capacity to track aortic growth in everyday practice. Aortic geometry mapping (AGM) via image registration of serial computed tomography angiograms outperforms manual assessment, providing accurate and reproducible 3D maps of aortic diameter and growth rate. This observational study aimed to evaluate the accuracy and reproducibility of AGM on non-gated contrast-enhanced (CE-) and cardiac- and respiratory-gated (GN-) magnetic resonance angiographies (MRA)., Methods: Patients with thoracic aortic disease followed with serial CE-MRA (n = 30) or GN-MRA (n = 15) acquired at least 1 year apart were retrospectively and consecutively identified. Two independent observers measured aortic diameters and growth rates (GR) manually at several thoracic aorta reference levels and with AGM. Agreement between manual and AGM measurements and their inter-observer reproducibility were compared. Reproducibility for aortic diameter and GR maps assessed with AGM was obtained., Results: Mean follow-up was 3.8 ± 2.3 years for CE- and 2.7 ± 1.6 years for GN-MRA. AGM was feasible in the 93% of CE-MRA pairs and in the 100% of GN-MRA pairs. Manual and AGM diameters showed excellent agreement and inter-observer reproducibility (ICC>0.9) at all anatomical levels. Agreement between manual and AGM GR was more limited, both in the aortic root by GN-MRA (ICC=0.47) and in the thoracic aorta, where higher accuracy was obtained with GN- than with CE-MRA (ICC=0.55 vs 0.43). The inter-observer reproducibility of GR by AGM was superior compared to manual assessment, both with CE- (thoracic: ICC= 0.91 vs 0.51) and GN-MRA (root: ICC=0.84 vs 0.52; thoracic: ICC=0.93 vs 0.60). AGM-based 3D aortic size and growth maps were highly reproducible (median ICC >0.9 for diameters and >0.80 for GR)., Conclusion: Mapping aortic diameter and growth on MRA via 3D image registration is feasible, accurate and outperforms the current manual clinical standard. This technique could broaden the possibilities of clinical and research evaluation of patients with aortic thoracic diseases., Competing Interests: Declaration of Competing Interest The authors declare that they have no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Prognostic impact of shock in patients with type A acute aortic syndrome. Results of a nationwide multicenter study.
- Author
-
Ferrera C, Vilacosta I, Rodríguez Palomares JF, Calvo Iglesias F, Barros-Membrilla AJ, Azqueta Molluna M, Mosquera V, Tarrío R, Revilla Orodea A, Toral Sepúlveda D, Ramos González-Cristóbal I, Maroto Castellanos L, Sao A, and Evangelista A
- Abstract
Objective: To evaluate the clinical characteristics, imaging findings, treatment, and prognosis of patients with type A acute aortic syndrome (AAS-A) presenting with shock. To assess the impact of surgery on this patient population., Methods: The study included 521 patients with A-AAS enrolled in the Spanish Registry of Acute Aortic Syndrome (RESA-III) from January 2018 to December 2019. The RESA-III is a prospective, multicenter registry that contains AAS data from 30 tertiary-care hospitals. Patients were classified into two groups according to their clinical presentation, with or without shock. Shock was defined as persistent systolic blood pressure <80 mmHg despite adequate volume resuscitation., Results: 97 (18.6%) patients with A-AAS presented with shock. Clinical presentation with syncope was much more common in the Shock group (45.4% vs 10.1%, p = 0.001). Patients in the Shock group had more complications at diagnosis and before surgery: cardiac tamponade (36.2% vs 9%, p < 0.001), acute renal failure (28.9% vs 18.2%, p = 0.018), and need for orotracheal intubation (40% vs 9.1%, p < 0.001). There were no significant differences in aortic regurgitation (51.6% vs 46.7%, p = 0.396) between groups. In-hospital mortality was higher among patients with shock (48.5% vs 27.4%, p < 0.001). Surgery was associated with a significant mortality reduction both in patients with and without shock. Surgery had an independent protective effect on mortality (OR 0.03, 95% CI (0.00-0.32))., Conclusion: Patients with AAS-A admitted with shock have a heavily increased risk of mortality. Syncope and pericardial effusion at diagnosis are strongly associated with shock. Surgery was independently associated with a mortality reduction in patients with AAS-A and shock., Competing Interests: Conflict of interest statement There are no potential conflicts of interest to declare., (Copyright © 2024 Hellenic Society of Cardiology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives.
- Author
-
Cabrera-Romero E, Ochoa JP, Barriales-Villa R, Bermúdez-Jiménez FJ, Climent-Payá V, Zorio E, Espinosa MA, Gallego-Delgado M, Navarro-Peñalver M, Arana-Achaga X, Piqueras-Flores J, Espejo-Bares V, Rodríguez-Palomares JF, Lacuey-Lecumberri G, López J, Tiron C, Peña-Peña ML, García-Pinilla JM, Lorca R, Ripoll-Vera T, Díez-López C, Mogollon MV, García-Álvarez A, Martínez-Dolz L, Brion M, Larrañaga-Moreira JM, Jiménez-Jáimez J, García-Álvarez MI, Vilches S, Villacorta E, Sabater-Molina M, Solla-Ruiz I, Royuela A, Domínguez F, Mirelis JG, and Garcia-Pavia P
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Young Adult, Connectin genetics, Electrocardiography, Follow-Up Studies, Spain epidemiology, Retrospective Studies, Cardiomyopathy, Dilated genetics, Cardiomyopathy, Dilated physiopathology, Genotype, Penetrance
- Abstract
Background: Disease penetrance in genotype-positive (G+) relatives of families with dilated cardiomyopathy (DCM) and the characteristics associated with DCM onset in these individuals are unknown., Objectives: This study sought to determine the penetrance of new DCM diagnosis in G+ relatives and to identify factors associated with DCM development., Methods: The authors evaluated 779 G+ patients (age 35.8 ± 17.3 years; 459 [59%] females; 367 [47%] with variants in TTN) without DCM followed at 25 Spanish centers., Results: After a median follow-up of 37.1 months (Q1-Q3: 16.3-63.8 months), 85 individuals (10.9%) developed DCM (incidence rate of 2.9 per 100 person-years; 95% CI: 2.3-3.5 per 100 person-years). DCM penetrance and age at DCM onset was different according to underlying gene group (log-rank P = 0.015 and P <0.01, respectively). In a multivariable model excluding CMR parameters, independent predictors of DCM development were: older age (HR per 1-year increase: 1.02; 95% CI: 1.0-1.04), an abnormal electrocardiogram (HR: 2.13; 95% CI: 1.38-3.29); presence of variants in motor sarcomeric genes (HR: 1.92; 95% CI: 1.05-3.50); lower left ventricular ejection fraction (HR per 1% increase: 0.86; 95% CI: 0.82-0.90) and larger left ventricular end-diastolic diameter (HR per 1-mm increase: 1.10; 95% CI: 1.06-1.13). Multivariable analysis in individuals with cardiac magnetic resonance and late gadolinium enhancement assessment (n = 360, 45%) identified late gadolinium enhancement as an additional independent predictor of DCM development (HR: 2.52; 95% CI: 1.43-4.45)., Conclusions: Following a first negative screening, approximately 11% of G+ relatives developed DCM during a median follow-up of 3 years. Older age, an abnormal electrocardiogram, lower left ventricular ejection fraction, increased left ventricular end-diastolic diameter, motor sarcomeric genetic variants, and late gadolinium enhancement are associated with a higher risk of developing DCM., Competing Interests: Funding Support and Author Disclosures This study was funded by the Spanish Society of Cardiology (Grant in Inherited Cardiac Diseases 2022) and the Instituto de Salud Carlos III through the projects “PI18/0004, PI20/0320” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The CNIC is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). The Hospital Universitario Puerta de Hierro, Hospital Clínic, Hospital Vall Hebron, Hospital Virgen del Rocío, Hospital Universitario Gregorio Marañon, and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart. The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction.
- Author
-
Amor-Salamanca A, Santana Rodríguez A, Rasoul H, Rodríguez-Palomares JF, Moldovan O, Hey TM, Delgado MG, Cuenca DL, de Castro Campos D, Basurte-Elorz MT, Macías-Ruiz R, Fuentes Cañamero ME, Galvin J, Bilbao Quesada R, de la Higuera Romero L, Trujillo-Quintero JP, García-Cruz LM, Cárdenas-Reyes I, Jiménez-Jáimez J, García-Hernández S, Valverde-Gómez M, Gómez-Díaz I, Limeres Freire J, García-Pinilla JM, Gimeno-Blanes JR, Savattis K, García-Pavía P, and Ochoa JP
- Subjects
- Male, Humans, Adolescent, Young Adult, Adult, Middle Aged, Female, Arrhythmias, Cardiac, Phenotype, T-Box Domain Proteins genetics, Cardiomyopathy, Dilated pathology, Heart Defects, Congenital genetics
- Abstract
Background: Less than 40% of patients with dilated cardiomyopathy (DCM) have a pathogenic/likely pathogenic genetic variant identified. TBX20 has been linked to congenital heart defects; although an association with left ventricular noncompaction (LVNC) and DCM has been proposed, it is still considered a gene with limited evidence for these phenotypes. This study sought to investigate the association between the TBX20 truncating variant ( TBX20tv ) and DCM/LVNC., Methods: TBX20 was sequenced by next-generation sequencing in 7463 unrelated probands with a diagnosis of DCM or LVNC, 22 773 probands of an internal comparison group (hypertrophic cardiomyopathy, channelopathies, or aortic diseases), and 124 098 external controls (individuals from the gnomAD database). Enrichment of TBX20tv in DCM/LVNC was calculated, cosegregation was determined in selected families, and clinical characteristics and outcomes were analyzed in carriers., Results: TBX20tv was enriched in DCM/LVNC (24/7463; 0.32%) compared with internal (1/22 773; 0.004%) and external comparison groups (4/124 098; 0.003%), with odds ratios of 73.23 (95% CI, 9.90-541.45; P <0.0001) and 99.76 (95% CI, 34.60-287.62; P <0.0001), respectively. TBX20tv was cosegregated with DCM/LVNC phenotype in 21 families for a combined logarythm of the odds score of 4.53 (strong linkage). Among 57 individuals with TBX20tv (49.1% men; mean age, 35.9±20.8 years), 41 (71.9%) exhibited DCM/LVNC, of whom 14 (34.1%) had also congenital heart defects. After a median follow-up of 6.9 (95% CI, 25-75:3.6-14.5) years, 9.7% of patients with DCM/LVNC had end-stage heart failure events and 4.8% experienced malignant ventricular arrhythmias., Conclusions: TBX20tv is associated with DCM/LVNC; congenital heart defect is also present in around one-third of cases. TBX20tv -associated DCM/LVNC is characterized by a nonaggressive phenotype, with a low incidence of major cardiovascular events. TBX20 should be considered a definitive gene for DCM and LVNC and routinely included in genetic testing panels for these phenotypes., Competing Interests: Disclosures Drs Amor-Salamanca, de la Higuera Romero, Cárdenas-Reyes, García-Hernández, Valverde-Gómez, Gómez-Díaz, and Ochoa are employees of Health in Code SL. The other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
20. Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation.
- Author
-
de Frutos F, Ochoa JP, Fernández AI, Gallego-Delgado M, Navarro-Peñalver M, Casas G, Basurte MT, Larrañaga-Moreira JM, Mogollón MV, Robles-Mezcua A, García-Granja PE, Climent V, Palomino-Doza J, García-Álvarez A, Brion M, Brugada R, Jiménez-Jáimez J, Bayes-Genis A, Ripoll-Vera T, Peña-Peña ML, Rodríguez-Palomares JF, Gonzalez-Carrillo J, Villacorta E, Espinosa MA, Garcia-Pavia P, and Mirelis JG
- Subjects
- Female, Humans, Middle Aged, Male, Contrast Media, Gadolinium, Stroke Volume, Ventricular Function, Left, Arrhythmias, Cardiac, Genetic Association Studies, Predictive Value of Tests, Magnetic Resonance Imaging, Cine, Adaptor Proteins, Signal Transducing genetics, Apoptosis Regulatory Proteins genetics, Cardiomyopathy, Dilated diagnostic imaging, Cardiomyopathy, Dilated genetics, Cardiomyopathy, Dilated complications
- Abstract
Aims: Late gadolinium enhancement (LGE) is frequently found in patients with dilated cardiomyopathy (DCM); there is little information about its frequency and distribution pattern according to the underlying genetic substrate. We sought to describe LGE patterns according to genotypes and to analyse the risk of major ventricular arrhythmias (MVA) according to patterns., Methods and Results: Cardiac magnetic resonance findings and LGE distribution according to genetics were performed in a cohort of 600 DCM patients followed at 20 Spanish centres. After exclusion of individuals with multiple causative gene variants or with variants in infrequent DCM-causing genes, 577 patients (34% females, mean age 53.5 years, left ventricular ejection fraction 36.9 ± 13.9%) conformed to the final cohort. A causative genetic variant was identified in 219 (38%) patients, and 147 (25.5%) had LGE. Significant differences were found comparing LGE patterns between genes (P < 0.001). LGE was absent or rare in patients with variants in TNNT2, RBM20, and MYH7 (0, 5, and 20%, respectively). Patients with variants in DMD, DSP, and FLNC showed a predominance of LGE subepicardial patterns (50, 41, and 18%, respectively), whereas patients with variants in TTN, BAG3, LMNA, and MYBPC3 showed unspecific LGE patterns. The genetic yield differed according to LGE patterns. Patients with subepicardial, lineal midwall, transmural, and right ventricular insertion points or with combinations of LGE patterns showed an increased risk of MVA compared with patients without LGE., Conclusion: LGE patterns in DCM have a specific distribution according to the affected gene. Certain LGE patterns are associated with an increased risk of MVA and with an increased yield of genetic testing., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
21. Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure.
- Author
-
Cannie DE, Syrris P, Protonotarios A, Bakalakos A, Pruny JF, Ditaranto R, Martinez-Veira C, Larrañaga-Moreira JM, Medo K, Bermúdez-Jiménez FJ, Ben Yaou R, Leturcq F, Mezcua AR, Marini-Bettolo C, Cabrera E, Reuter C, Limeres Freire J, Rodríguez-Palomares JF, Mestroni L, Taylor MRG, Parikh VN, Ashley EA, Barriales-Villa R, Jiménez-Jáimez J, Garcia-Pavia P, Charron P, Biagini E, García Pinilla JM, Bourke J, Savvatis K, Wahbi K, and Elliott PM
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac genetics, Arrhythmias, Cardiac complications, Mutation, X-Linked Emery-Dreifuss Muscular Dystrophy complications, Heart Diseases complications, Muscular Dystrophy, Emery-Dreifuss complications, Muscular Dystrophy, Emery-Dreifuss genetics, Muscular Dystrophy, Emery-Dreifuss pathology, Heart Failure etiology, Heart Failure complications
- Abstract
Background and Aims: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterize the cardiac complications of EMD variants., Methods: Consecutively referred EMD variant-carriers were retrospectively recruited from 12 international cardiomyopathy units. MVA and ESHF incidences in male and female variant-carriers were determined. Male EMD variant-carriers with a cardiac phenotype at baseline (EMDCARDIAC) were compared with consecutively recruited male LMNA variant-carriers with a cardiac phenotype at baseline (LMNACARDIAC)., Results: Longitudinal follow-up data were available for 38 male and 21 female EMD variant-carriers [mean (SD) ages 33.4 (13.3) and 43.3 (16.8) years, respectively]. Nine (23.7%) males developed MVA and five (13.2%) developed ESHF during a median (inter-quartile range) follow-up of 65.0 (24.3-109.5) months. No female EMD variant-carrier had MVA or ESHF, but nine (42.8%) developed a cardiac phenotype at a median (inter-quartile range) age of 58.6 (53.2-60.4) years. Incidence rates for MVA were similar for EMDCARDIAC and LMNACARDIAC (4.8 and 6.6 per 100 person-years, respectively; log-rank P = .49). Incidence rates for ESHF were 2.4 and 5.9 per 100 person-years for EMDCARDIAC and LMNACARDIAC, respectively (log-rank P = .09)., Conclusions: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
22. MRI Investigation of the Differential Impact of Left Ventricular Ejection Fraction After Myocardial Infarction in Elderly vs. Nonelderly Patients to Predict Readmission for Heart Failure.
- Author
-
Marcos-Garcés V, Merenciano-González H, Gavara J, Gabaldón-Pérez A, López-Lereu MP, Monmeneu JV, Nuñez J, Pérez N, Ríos-Navarro C, de Dios E, Chorro FJ, Valente F, Lorenzatti D, Domenech-Ximenos B, Alonso Tello A, Maymí-Ballesteros M, Rello-Sabaté P, Morr CI, Ortiz-Pérez JT, Rodríguez-Palomares JF, and Bodí V
- Subjects
- Humans, Aged, Ventricular Function, Left, Stroke Volume, Contrast Media, Prospective Studies, Patient Readmission, Gadolinium, Magnetic Resonance Imaging methods, Prognosis, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction complications, Myocardial Infarction complications, Heart Failure
- Abstract
Background: Patients with ST-segment elevation myocardial infarction (STEMI), especially elderly individuals, have an increased risk of readmission for acute heart failure (AHF)., Purpose: To study the impact of left ventricular ejection fraction (LVEF) by MRI to predict AHF in elderly (>70 years) and nonelderly patients after STEMI., Study Type: Prospective., Population: Multicenter registry of 759 reperfused STEMI patients (23.3% elderly)., Field Strength/sequence: 1.5-T. Balanced steady-state free precession (cine imaging) and segmented inversion recovery steady-state free precession (late gadolinium enhancement) sequences., Assessment: One-week MRI-derived LVEF (%) was quantified. Sequential MRI data were recorded in 579 patients. Patients were categorized according to their MRI-derived LVEF as preserved (p-LVEF, ≥50%), mildly reduced (mr-LVEF, 41%-49%), or reduced (r-LVEF, ≤40%). Median follow-up was 5 [2.33-7.54] years., Statistical Tests: Univariable (Student's t, Mann-Whitney U, chi-square, and Fisher's exact tests) and multivariable (Cox proportional hazard regression) comparisons and continuous-time multistate Markov model to analyze transitions between LVEF categories and to AHF. Hazard ratios (HR) with 95% confidence intervals (CIs) were computed. P < 0.05 was considered statistically significant., Results: Over the follow-up period, 79 (10.4%) patients presented AHF. MRI-LVEF was the most robust predictor in nonelderly (HR 0.94 [0.91-0.98]) and elderly patients (HR 0.94 [0.91-0.97]). Elderly patients had an increased AHF risk across the LVEF spectrum. An excess of risk (compared to p-LVEF) was noted in patients with r-LVEF both in nonelderly (HR 11.25 [5.67-22.32]) and elderly patients (HR 7.55 [3.29-17.34]). However, the mr-LVEF category was associated with increased AHF risk only in elderly patients (HR 3.66 [1.54-8.68]). Less transitions to higher LVEF states (n = 19, 30.2% vs. n = 98, 53%) and more transitions to AHF state (n = 34, 53.9% vs. n = 45, 24.3%) were observed in elderly than nonelderly patients., Data Conclusion: MRI-derived p-LVEF confers a favorable prognosis and r-LVEF identifies individuals at the highest risk of AHF in both elderly and nonelderly patients. Nevertheless, an excess of risk was also found in the mr-LVEF category in the elderly group., Evidence Level: 2., Technical Efficacy: Stage 2., (© 2023 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
23. Mechanisms of Aortic Dilation in Patients With Bicuspid Aortic Valve: JACC State-of-the-Art Review.
- Author
-
Rodríguez-Palomares JF, Dux-Santoy L, Guala A, Galian-Gay L, and Evangelista A
- Subjects
- Humans, Aortic Valve diagnostic imaging, Aortic Valve abnormalities, Dilatation, Bicuspid Aortic Valve Disease, Heart Valve Diseases complications, Heart Valve Diseases epidemiology, Aortic Diseases complications
- Abstract
Bicuspid aortic valve is the most common congenital heart disease and exposes patients to an increased risk of aortic dilation and dissection. Aortic dilation is a slow, silent process, leading to a greater risk of aortic dissection. The prevention of adverse events together with optimization of the frequency of the required lifelong imaging surveillance are important for both clinicians and patients and motivated extensive research to shed light on the physiopathologic processes involved in bicuspid aortic valve aortopathy. Two main research hypotheses have been consolidated in the last decade: one supports a genetic basis for the increased prevalence of dilation, in particular for the aortic root, and the second supports the damaging impact on the aortic wall of altered flow dynamics associated with these structurally abnormal valves, particularly significant in the ascending aorta. Current opinion tends to rule out mutually excluding causative mechanisms, recognizing both as important and potentially clinically relevant., Competing Interests: Funding Support and Author Disclosures This work was supported by funding from the Instituto de Salud Carlos III (projects ICI14/00197, PI17/00381 and PI20/01727); the Spanish Ministry of Science, Innovation, and Universities (RTC2019-007280-1); the Spanish Society of Cardiology (SEC/FEC-INV-CLI 20/015 and SEC/FEC-INV-CLI 21/030); and the Biomedical Research Networking Center on Cardiovascular Diseases. Dr Guala has received funding from the Spanish Ministry of Science, Innovation and Universities (IJC2018-037349-I) and from “la Caixa” Foundation (LCF/BQ/PR22/11920008). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis.
- Author
-
Galian-Gay L, Teixidó-Turà G, Casas G, Ferrer-Sistach E, Mitroi C, Mingo S, Monivas V, Saura D, Vidal B, Moral S, Calvo F, Sánchez V, Gonzalez A, Guzman-Martínez G, Noris Mora M, Arnau Vives MÁ, Peteiro J, Bouzas A, González-Alujas T, Gutiérrez L, Fernandez-Galera R, Valente F, Guala A, Ruiz-Muñoz A, Dux-Santoy L, Oliveró Soldevila R, Avilés AS, Rodríguez Palomares JF, Ferreira-González I, and Evangelista A
- Subjects
- Humans, Echocardiography, Aortic Valve diagnostic imaging, Ventricular Function, Left, Stroke Volume, Severity of Illness Index, Treatment Outcome, Retrospective Studies, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery
- Abstract
Aims: To assess the progression of the disease and evolution of the main echocardiographic variables for quantifying AS in patients with severe low-flow low-gradient (LFLG) AS compared to other severe AS subtypes., Methods and Results: Longitudinal, observational, multicenter study including consecutive asymptomatic patients with severe AS (aortic valve area, AVA < 1.0 cm²) and normal left ventricle ejection fraction (LVEF ≥ 50%). Patients were classified according to baseline echocardiography into: HG (high gradient; mean gradient ≥ 40 mmHg), NFLG (normal-flow low-gradient; mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35mL/m2), or LFLG (mean gradient < 40 mmHg, SVi ≤ 35 mL/m²). AS progression was analyzed by comparing patients' baseline measurements and their last follow-up measurements or those taken prior to aortic valve replacement (AVR). Of the 903 included patients, 401 (44.4%) were HG, 405 (44.9%) NFLG, and 97 (10.7%) LFLG. Progression of the mean gradient in a linear mixed regression model was greater in low-gradient groups: LFLG vs. HG (regression coefficient 0.124, P = 0.005) and NFLG vs. HG (regression coefficient 0.068, P = 0.018). No differences were observed between the LFLG and NFLG groups (regression coefficient 0.056, P = 0.195). However, AVA reduction was slower in the LFLG group compared to the NFLG (P < 0.001). During follow-up, in conservatively-managed patients, 19.1% (n = 9) of LFLG patients evolved to having NFLG AS and 44.7% (n = 21) to having HG AS. In patients undergoing AVR, 58.0% (n = 29) of LFLG baseline patients received AVR with a HG AS., Conclusion: LFLG AS shows an intermediate AVA and gradient progression compared to NFLG and HG AS. The majority of patients initially classified as having LFLG AS changed over time to having other severe forms of AS, and most of them received AVR with a HG AS., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
25. Impact of Persistent Microvascular Obstruction Late After STEMI on Adverse LV Remodeling: A CMR Study.
- Author
-
Bodi V, Gavara J, Lopez-Lereu MP, Monmeneu JV, de Dios E, Perez-Sole N, Bonanad C, Marcos-Garces V, Canoves J, Minana G, Nunez J, Moratal D, Chorro FJ, Rodríguez-Palomares JF, Freixa A, Borrás R, Ortiz-Pérez JT, and Rios-Navarro C
- Subjects
- Humans, Predictive Value of Tests, Magnetic Resonance Imaging, Heart, Microcirculation, Ventricular Remodeling, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction therapy, ST Elevation Myocardial Infarction complications, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Little is known about the occurrence and implications of persistent microvascular obstruction (MVO) after reperfused ST-segment elevation myocardial infarction (STEMI)., Objectives: The authors used cardiac magnetic resonance (CMR) to characterize the impact of persistent MVO on adverse left ventricular remodeling (ALVR)., Methods: A prospective registry of 471 STEMI patients underwent CMR 7 (IQR: 5-10) days and 198 (IQR: 167-231) days after infarction. MVO (≥1 segment) and ALVR (relative increase >15% at follow-up CMR) of left ventricular end-diastolic index (LVEDVI) and left ventricular end-systolic volume index (LVESVI) were determined., Results: One-week MVO occurred in 209 patients (44%) and persisted in 30 (6%). The extent of MVO (P = 0.026) and intramyocardial hemorrhage (P = 0.001) at 1 week were independently associated with the magnitude of MVO at follow-up CMR. Compared with patients without MVO (n = 262, 56%) or with MVO only at 1 week (n = 179, 38%), those with persistent MVO at follow-up (n = 30, 6%) showed higher rates of ALVR-LVEDVI (22%, 27%, and 50%; P = 0.003) and ALVR-LVESVI (20%, 21%, and 53%; P < 0.001). After adjustment, persistent MVO at follow-up (≥1 segment) was independently associated with ΔLVEDVI (relative increase, %) (P < 0.001) and ΔLVESVI (P < 0.001). Compared with a 1:1 propensity score-matched population on CMR variables made up of 30 patients with MVO only at 1 week, patients with persistent MVO more frequently displayed ALVR-LVEDVI (12% vs 50%; P = 0.003) and ALVR-LVESVI (12% vs 53%; P = 0.001)., Conclusions: MVO persists in a small percentage of patients in chronic phase after STEMI and exerts deleterious effects in terms of LV remodeling. These findings fuel the need for further research on microvascular injury repair., Competing Interests: Funding Support and Author Disclosures This work was supported by Instituto de Salud Carlos III and Fondos Europeos de Desarrollo Regional FEDER (grant numbers PI20/00637, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479, and a postgraduate contract CM21/00175 to V.M.-G.), by Conselleria de Educación–Generalitat Valenciana (PROMETEO/2021/008) and by Sociedad Española de Cardiología (grant SEC/FEC-INV-CLI 21/024). Dr Gavara has received financial support from the Agencia Estatal de Investigación (grant FJC2020-043981-I/AEI/10.13039/501100011033). Dr Moratal has received financial support from the Conselleria d’Educació, Investigació, Cultura i Esport, Generalitat Valenciana (grants AEST/2019/037, AEST/2020/029). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
26. Magnetic resonance in patients with cardiovascular devices. SEC-GT CRMTC/SEC-Heart Rhythm Association/SERAM/SEICAT consensus document.
- Author
-
Barreiro-Pérez M, Cabeza B, Calvo D, Reyes-Juárez JL, Datino T, Vañó Galván E, Maceira González AM, Delgado Sánchez-Gracián C, Prat-González S, Perea RJ, Bastarrika G, Sánchez M, Jiménez-Borreguero LJ, Fernández-Golfín Lobán C, Rodríguez Palomares JF, Tolosana JM, Hidalgo Pérez JA, Pérez-David E, Bertomeu-González V, and Cuéllar H
- Subjects
- Humans, Consensus, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Heart Diseases, Cardiology
- Abstract
Magnetic resonance has become a first-line imaging modality in various clinical scenarios. The number of patients with different cardiovascular devices, including cardiac implantable electronic devices, has increased exponentially. Although there have been reports of risks associated with exposure to magnetic resonance in these patients, the clinical evidence now supports the safety of performing these studies under specific conditions and following recommendations to minimize possible risks. This document was written by the Working Group on Cardiac Magnetic Resonance Imaging and Cardiac Computed Tomography of the Spanish Society of Cardiology (SEC-GT CRMTC), the Heart Rhythm Association of the Spanish Society of Cardiology (SEC-Heart Rhythm Association), the Spanish Society of Medical Radiology (SERAM), and the Spanish Society of Cardiothoracic Imaging (SEICAT). The document reviews the clinical evidence available in this field and establishes a series of recommendations so that patients with cardiovascular devices can safely access this diagnostic tool., (Copyright © 2022 SERAM. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk.
- Author
-
Consegal M, Barba I, García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Valente F, Carmona MÁ, Miró-Casas E, Sambola A, Lidón RM, Bañeras J, Barrabés JA, Rodríguez C, Benito B, Ruiz-Meana M, Inserte J, Ferreira-González I, and Rodríguez-Sinovas A
- Subjects
- Animals, Magnetic Resonance Imaging, Reperfusion, Succinic Acid, Swine, Treatment Outcome, Heart Failure, Myocardial Infarction pathology, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction
- Abstract
Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by
1 H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p < 0.05). However, regression analysis did not detect any significant correlation between most metabolite concentrations and infarct size, extent of edema or other cardiac magnetic resonance (CMR) variables. In conclusion, spontaneous reperfusion in TIMI 2 patients associates with enhanced succinate levels in peripheral blood, suggesting that succinate release increases overtime following reperfusion. However, early plasma levels of succinate and other metabolites obtained from peripheral blood does not correlate with the degree of irreversible injury or area at risk in STEMI patients, and cannot be considered as predictors of CMR variables.Trial registration: Registered at www.clinicaltrials.gov (NCT02404376) on 31/03/2015. EudraCT number: 2015-001000-58., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
28. Myocardial Fibrosis at Cardiac MRI Helps Predict Adverse Clinical Outcome in Patients with Mitral Valve Prolapse.
- Author
-
Figliozzi S, Georgiopoulos G, Lopes PM, Bauer KB, Moura-Ferreira S, Tondi L, Mushtaq S, Censi S, Pavon AG, Bassi I, Servato ML, Teske AJ, Biondi F, Filomena D, Pica S, Torlasco C, Muraru D, Monney P, Quattrocchi G, Maestrini V, Agati L, Monti L, Pedrotti P, Vandenberk B, Squeri A, Lombardi M, Ferreira AM, Schwitter J, Aquaro GD, Chiribiri A, Rodríguez Palomares JF, Yilmaz A, Andreini D, Florian A, Leiner T, Abecasis J, Badano LP, Bogaert J, and Masci PG
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Contrast Media, Gadolinium, Mitral Valve, Magnetic Resonance Imaging, Fibrosis, Death, Sudden, Cardiac, Mitral Valve Prolapse complications, Mitral Valve Insufficiency, Cardiomyopathies, Ventricular Dysfunction, Left
- Abstract
Background Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence ( P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severity and sustained VT and aborted SCD at baseline (area under the receiver operating characteristic curve, 0.70 vs 0.62; P = .03). Conclusion In contrast to mitral annulus disjunction, myocardial fibrosis determined according to late gadolinium enhancement at cardiac MRI was associated with adverse outcome in patients with mitral valve prolapse without moderate-to-severe mitral regurgitation or left ventricular dysfunction. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Gerber in this issue.
- Published
- 2023
- Full Text
- View/download PDF
29. Left ventricular noncompaction: a disease or a phenotypic trait?
- Author
-
Casas G, Rodríguez-Palomares JF, and Ferreira-González I
- Subjects
- Humans, Echocardiography, Heart Ventricles, Phenotype, Cardiomyopathies diagnosis, Cardiomyopathies genetics, Cardiomyopathies therapy, Heart Defects, Congenital complications
- Abstract
Left ventricular noncompaction is a poorly defined and controversial entity, with wide phenotypic expression: from a simple anatomical trait to a disease with overt cardiac affection. Current diagnostic criteria rely exclusively on morphologic features of hypertrabeculation, which have low specificity for identifying true cardiomyopathy cases. The management of left ventricular noncompaction is also heterogeneous, and there are no dedicated clinical practice guidelines. The most common cardiovascular complications are heart failure, ventricular arrhythmias, and systemic embolisms. In this review, we discuss the diagnostic limitations of the available criteria, and propose a comprehensive alternative approach (including functional imaging variables, tissue characterization, genetics, and family screening) that may help in the differential diagnosis of hypertrabeculation cases. We also describe the genetic background of the disease and discuss the overlap with other cardiomyopathies. Finally, we focus on controversial issues in clinical management and suggest the use of the previously-mentioned variables for risk stratification and for individualization of patient follow-up., (Copyright © 2022 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients.
- Author
-
Gabaldón-Pérez A, Marcos-Garcés V, Gavara J, López-Lereu MP, Monmeneu JV, Pérez N, Ríos-Navarro C, de Dios E, Merenciano-González H, Cànoves J, Racugno P, Bonanad C, Minana G, Núnez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, and Bodí V
- Subjects
- Humans, Aged, Aged, 80 and over, Stroke Volume, Prognosis, Ventricular Function, Left, Predictive Value of Tests, Magnetic Resonance Spectroscopy, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction therapy, ST Elevation Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: older patients with ST-segment elevation myocardial infarction (STEMI) represent a very high-risk population. Data on the prognostic value of cardiac magnetic resonance (CMR) in this scenario are scarce., Methods: the registry comprised 247 STEMI patients over 70 years of age treated with percutaneous intervention and included in a multicenter registry. Baseline characteristics, echocardiographic parameters and CMR-derived left ventricular ejection fraction (LVEF, %), infarct size (% of left ventricular mass) and microvascular obstruction (MVO, number of segments) were prospectively collected. The additional prognostic power of CMR was assessed using adjusted C-statistic, net reclassification index (NRI) and integrated discrimination improvement index (IDI)., Results: during a 4.8-year mean follow-up, the number of first major adverse cardiac events (MACE) was 66 (26.7%): 27 all-cause deaths and 39 re-admissions for acute heart failure. Predictors of MACE were GRACE score (HR 1.03 [1.02-1.04], P < 0.001), CMR-LVEF (HR 0.97 [0.95-0.99] per percent increase, P = 0.006) and MVO (HR 1.24 [1.09-1.4] per segment, P = 0.001). Adding CMR data significantly improved MACE prediction compared to the model with baseline and echocardiographic characteristics (C-statistic 0.759 [0.694-0.824] vs. 0.685 [0.613-0.756], NRI = 0.6, IDI = 0.08, P < 0.001). The best cut-offs for independent variables were GRACE score > 155, LVEF < 40% and MVO ≥ 2 segments. A simple score (0, 1, 2, 3) based on the number of altered factors accurately predicted the MACE per 100 person-years: 0.78, 5.53, 11.51 and 78.79, respectively (P < 0.001)., Conclusions: CMR data contribute valuable prognostic information in older patients submitted to undergo CMR soon after STEMI. The Older-STEMI-CMR score should be externally validated., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
31. Natural History of MYH7-Related Dilated Cardiomyopathy.
- Author
-
de Frutos F, Ochoa JP, Navarro-Peñalver M, Baas A, Bjerre JV, Zorio E, Méndez I, Lorca R, Verdonschot JAJ, García-Granja PE, Bilinska Z, Fatkin D, Fuentes-Cañamero ME, García-Pinilla JM, García-Álvarez MI, Girolami F, Barriales-Villa R, Díez-López C, Lopes LR, Wahbi K, García-Álvarez A, Rodríguez-Sánchez I, Rekondo-Olaetxea J, Rodríguez-Palomares JF, Gallego-Delgado M, Meder B, Kubanek M, Hansen FG, Restrepo-Córdoba MA, Palomino-Doza J, Ruiz-Guerrero L, Sarquella-Brugada G, Perez-Perez AJ, Bermúdez-Jiménez FJ, Ripoll-Vera T, Rasmussen TB, Jansen M, Sabater-Molina M, Elliot PM, and Garcia-Pavia P
- Subjects
- Adolescent, Adult, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac genetics, Cardiac Myosins genetics, Female, Humans, Male, Middle Aged, Phenotype, Ventricular Remodeling genetics, Young Adult, Cardiomyopathy, Dilated genetics, Heart Failure complications, Heart Failure genetics, Myosin Heavy Chains genetics
- Abstract
Background: Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described., Objectives: We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression., Methods: We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 ± 19.2 years) recruited from 29 international centers., Results: At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% ± 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of ≤35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants., Conclusions: MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare., Competing Interests: Funding Support and Author Disclosures This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI18/0004, PI20/0320, and PT17/0015/0043 (cofunded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). The Hospital Universitario Puerta de Hierro, the Hospital Sant Joan de Déu, and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart. Dr de Frutos receives grant support from ISCIII (CM20/00101). Genetic examinations of Polish patients were funded with DETECTIN-HF grant from the ERA-CVD framework, NCBiR. Dr Baas has received funding from CVON2020B005 DOUBLE-DOSE, Dutch Heart Foundation (Dekker 2015T041). Dr Fatkin has received funding from Victor Chang Cardiac Research Institute and NSW Health. Dr Lopes is funded by an MRC UK Clinical Academic Research Partnership award (MR/T005181/1). Dr Meder has received funding from the Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research) and Informatics for Life (Klaus Tschira Foundation). Dr Kubanek has received grant support from the Ministry of Health, Czech Republic (NV19-08-00122) and IPO (Institute for Clinical and Experimental Medicine–IKEM, IN 00023001). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Domain generalization in deep learning for contrast-enhanced imaging.
- Author
-
Sendra-Balcells C, Campello VM, Martín-Isla C, Viladés D, Descalzo ML, Guala A, Rodríguez-Palomares JF, and Lekadir K
- Subjects
- Heart, Heart Ventricles, Image Processing, Computer-Assisted methods, Magnetic Resonance Imaging methods, Neural Networks, Computer, Deep Learning
- Abstract
Background: The domain generalization problem has been widely investigated in deep learning for non-contrast imaging over the last years, but it received limited attention for contrast-enhanced imaging. However, there are marked differences in contrast imaging protocols across clinical centers, in particular in the time between contrast injection and image acquisition, while access to multi-center contrast-enhanced image data is limited compared to available datasets for non-contrast imaging. This calls for new tools for generalizing single-domain, single-center deep learning models across new unseen domains and clinical centers in contrast-enhanced imaging., Methods: In this paper, we present an exhaustive evaluation of deep learning techniques to achieve generalizability to unseen clinical centers for contrast-enhanced image segmentation. To this end, several techniques are investigated, optimized and systematically evaluated, including data augmentation, domain mixing, transfer learning and domain adaptation. To demonstrate the potential of domain generalization for contrast-enhanced imaging, the methods are evaluated for ventricular segmentation in contrast-enhanced cardiac magnetic resonance imaging (MRI)., Results: The results are obtained based on a multi-center cardiac contrast-enhanced MRI dataset acquired in four hospitals located in three countries (France, Spain and China). They show that the combination of data augmentation and transfer learning can lead to single-center models that generalize well to new clinical centers not included during training., Conclusions: Single-domain neural networks enriched with suitable generalization procedures can reach and even surpass the performance of multi-center, multi-vendor models in contrast-enhanced imaging, hence eliminating the need for comprehensive multi-center datasets to train generalizable models., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy.
- Author
-
Escobar-Lopez L, Ochoa JP, Royuela A, Verdonschot JAJ, Dal Ferro M, Espinosa MA, Sabater-Molina M, Gallego-Delgado M, Larrañaga-Moreira JM, Garcia-Pinilla JM, Basurte-Elorz MT, Rodríguez-Palomares JF, Climent V, Bermudez-Jimenez FJ, Mogollón-Jiménez MV, Lopez J, Peña-Peña ML, Garcia-Alvarez A, López-Abel B, Ripoll-Vera T, Palomino-Doza J, Bayes-Genis A, Brugada R, Idiazabal U, Mirelis JG, Dominguez F, Henkens MTHM, Krapels IPC, Brunner HG, Paldino A, Zaffalon D, Mestroni L, Sinagra G, Heymans SRB, Merlo M, and Garcia-Pavia P
- Subjects
- Cohort Studies, Genotype, Humans, Risk Factors, Cardiomyopathy, Dilated diagnosis, Cardiomyopathy, Dilated genetics, Ventricular Dysfunction, Left
- Abstract
Background: Although genotyping allows family screening and influences risk-stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), its result is negative in a significant number of patients, limiting its widespread adoption., Objectives: This study sought to develop and externally validate a score that predicts the probability for a positive genetic test result (G+) in DCM/LVSD., Methods: Clinical, electrocardiogram, and echocardiographic variables were collected in 1,015 genotyped patients from Spain with DCM/LVSD. Multivariable logistic regression analysis was used to identify variables independently predicting G+, which were summed to create the Madrid Genotype Score. The external validation sample comprised 1,097 genotyped patients from the Maastricht and Trieste registries., Results: A G+ result was found in 377 (37%) and 289 (26%) patients from the derivation and validation cohorts, respectively. Independent predictors of a G+ result in the derivation cohort were: family history of DCM (OR: 2.29; 95% CI: 1.73-3.04; P < 0.001), low electrocardiogram voltage in peripheral leads (OR: 3.61; 95% CI: 2.38-5.49; P < 0.001), skeletal myopathy (OR: 3.42; 95% CI: 1.60-7.31; P = 0.001), absence of hypertension (OR: 2.28; 95% CI: 1.67-3.13; P < 0.001), and absence of left bundle branch block (OR: 3.58; 95% CI: 2.57-5.01; P < 0.001). A score containing these factors predicted a G+ result, ranging from 3% when all predictors were absent to 79% when ≥4 predictors were present. Internal validation provided a C-statistic of 0.74 (95% CI: 0.71-0.77) and a calibration slope of 0.94 (95% CI: 0.80-1.10). The C-statistic in the external validation cohort was 0.74 (95% CI: 0.71-0.78)., Conclusions: The Madrid Genotype Score is an accurate tool to predict a G+ result in DCM/LVSD., Competing Interests: Funding Support and Author Disclosures This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) (PI17/01941, PI18/0004, PI19/01283, PI20/0320) (co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future"). The CNIC is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). This study was also supported by the Netherlands Cardiovascular Research Initiative, an initiative with support from the Dutch Heart Foundation, DCVA Double Dosis 2020B005. The Hospital Universitario Puerta de Hierro, the Hospital Universitario Virgen de la Arrixaca and the Azienda Sanitaria Universitaria Giuliano-Isontina are members of the European Reference Network for rare, low-prevalence, and complex diseases of the heart (ERN GUARD-Heart). Dr Ochoa is an employee of Health in Code. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Magnetic Resonance Assessment of Left Ventricular Ejection Fraction at Any Time Post-Infarction for Prediction of Subsequent Events in a Large Multicenter STEMI Registry.
- Author
-
Gavara J, Marcos-Garces V, Lopez-Lereu MP, Monmeneu JV, Rios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, Cànoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodríguez-Palomares JF, Ortiz-Pérez JT, and Bodi V
- Subjects
- Contrast Media, Gadolinium, Humans, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging, Cine methods, Magnetic Resonance Spectroscopy, Predictive Value of Tests, Prognosis, Prospective Studies, Registries, Stroke Volume, Ventricular Function, Left, Percutaneous Coronary Intervention adverse effects, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction etiology
- Abstract
Background: Magnetic resonance imaging (MRI) is the most accurate imaging technique for left ventricular ejection fraction (LVEF) quantification, but as yet the prognostic value of LVEF assessment at any time after ST-segment elevation myocardial infarction (STEMI) for subsequent major adverse cardiac event (MACE) prediction is uncertain., Purpose: To explore the prognostic impact of MRI-derived LVEF at any time post-STEMI to predict subsequent MACE (cardiovascular death or re-admission for acute heart failure)., Study Type: Prospective., Population: One thousand thirteen STEMI patients were included in a multicenter registry., Field Strength/sequence: 1.5-T. Balanced steady-state free precession (cine imaging) and segmented inversion recovery steady-state free precession (late gadolinium enhancement) sequences., Assessment: Post-infarction MRI-derived LVEF (reduced [r]: <40%; mid-range [mr]: 40%-49%; preserved [p]: ≥50%) was sequentially quantified at 1 week and after >3 months of follow-up., Statistical Tests: Multi-state Markov model to determine the prognostic value of each LVEF state (r-, mr- or p-) at any time point assessed to predict subsequent MACE. A P-value <0.05 was considered to be statistically significant., Results: During a 6.2-year median follow-up, 105 MACE (10%) were registered. Transitions toward improved LVEF predominated and only r-LVEF (at any time assessed) was significantly related to a higher incidence of subsequent MACE. The observed transitions from r-LVEF, mr-LVEF, and p-LVEF states to MACE were: 15.3%, 6%, and 6.7%, respectively. Regarding the adjusted transition intensity ratios, patients in r-LVEF state were 4.52-fold more likely than those in mr-LVEF state and 5.01-fold more likely than those in p-LVEF state to move to MACE state. Nevertheless, no significant differences were found in transitions from mr-LVEF and p-LVEF states to MACE state (P-value = 0.6)., Data Conclusion: LVEF is an important MRI index for simple and dynamic post-STEMI risk stratification. Detection of r-LVEF by MRI at any time during follow-up identifies a subset of patients at high risk of subsequent events., Level of Evidence: 2 TECHNICAL EFFICACY STAGE: 2., (© 2021 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC. on behalf of International Society for Magnetic Resonance in Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
35. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
- Author
-
Mirelis JG, Escobar-Lopez L, Ochoa JP, Espinosa MÁ, Villacorta E, Navarro M, Casas G, Mora-Ayestarán N, Barriales-Villa R, Mogollón-Jiménez MV, García-Pinilla JM, García-Granja PE, Climent V, Palomino-Doza J, García-Álvarez A, Álvarez-Barredo M, Cabrera-Borrego E, Ripoll-Vera T, Peña-Peña ML, Rodríguez-González E, Gallego-Delgado M, Gonzalez-Carrillo J, Fernández-Ávila A, Rodríguez-Palomares JF, Brugada R, Bayes-Genis A, Dominguez F, and García-Pavía P
- Subjects
- Arrhythmias, Cardiac, Cicatrix, Contrast Media, Female, Gadolinium, Genotype, Humans, Magnetic Resonance Imaging, Cine, Male, Predictive Value of Tests, Prognosis, Retrospective Studies, Cardiomyopathy, Dilated, Heart Failure diagnosis, Heart Failure genetics
- Abstract
Aims: Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM., Methods and Results: Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenic/likely pathogenic variants (positive genotype) and 151 (25.2%) had LGE. In survival analysis, positive LGE was associated with MVA and ESHF (both, p < 0.001) while positive genotype was associated with ESHF (p = 0.034) but not with MVA (p = 0.102). Classification of patients according to genotype (G+/G-) and LGE presence (L+/L-) revealed progressively increasing events across L-/G-, L-/G+, L+/G- and L+/G+ groups and resulted in optimized MVA and ESHF prediction (p < 0.001 and p = 0.001, respectively). Hazard ratios for MVA and ESHF in patients with either L+ or G+ compared with those with L-/G- were 4.71 (95% confidence interval: 2.11-10.50, p < 0.001) and 7.92 (95% confidence interval: 1.86-33.78, p < 0.001), respectively., Conclusion: Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Scar assessment with CMR and genotyping should be considered to select patients for primary prevention implantable cardioverter-defibrillator placement., (© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
36. Fully Three-Dimensional Hemodynamic Characterization of Altered Blood Flow in Bicuspid Aortic Valve Patients With Respect to Aortic Dilatation: A Finite Element Approach.
- Author
-
Sotelo J, Franco P, Guala A, Dux-Santoy L, Ruiz-Muñoz A, Evangelista A, Mella H, Mura J, Hurtado DE, Rodríguez-Palomares JF, and Uribe S
- Abstract
Background and Purpose: Prognostic models based on cardiovascular hemodynamic parameters may bring new information for an early assessment of patients with bicuspid aortic valve (BAV), playing a key role in reducing the long-term risk of cardiovascular events. This work quantifies several three-dimensional hemodynamic parameters in different patients with BAV and ranks their relationships with aortic diameter., Materials and Methods: Using 4D-flow CMR data of 74 patients with BAV (49 right-left and 25 right-non-coronary) and 48 healthy volunteers, aortic 3D maps of seventeen 17 different hemodynamic parameters were quantified along the thoracic aorta. Patients with BAV were divided into two morphotype categories, BAV-Non-AAoD (where we include 18 non-dilated patients and 7 root-dilated patients) and BAV-AAoD (where we include the 49 patients with dilatation of the ascending aorta). Differences between volunteers and patients were evaluated using MANOVA with Pillai's trace statistic, Mann-Whitney U test, ROC curves, and minimum redundancy maximum relevance algorithm. Spearman's correlation was used to correlate the dilation with each hemodynamic parameter., Results: The flow eccentricity, backward velocity, velocity angle, regurgitation fraction, circumferential wall shear stress, axial vorticity, and axial circulation allowed to discriminate between volunteers and patients with BAV, even in the absence of dilation. In patients with BAV, the diameter presented a strong correlation (> |+/-0.7|) with the forward velocity and velocity angle, and a good correlation (> |+/-0.5|) with regurgitation fraction, wall shear stress, wall shear stress axial, and vorticity, also for morphotypes and phenotypes, some of them are correlated with the diameter. The velocity angle proved to be an excellent biomarker in the differentiation between volunteers and patients with BAV, BAV morphotypes, and BAV phenotypes, with an area under the curve bigger than 0.90, and higher predictor important scores., Conclusions: Through the application of a novel 3D quantification method, hemodynamic parameters related to flow direction, such as flow eccentricity, velocity angle, and regurgitation fraction, presented the best relationships with a local diameter and effectively differentiated patients with BAV from healthy volunteers., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sotelo, Franco, Guala, Dux-Santoy, Ruiz-Muñoz, Evangelista, Mella, Mura, Hurtado, Rodríguez-Palomares and Uribe.)
- Published
- 2022
- Full Text
- View/download PDF
37. Registration-based semi-automatic assessment of aortic diameter growth rate from contrast-enhanced computed tomography outperforms manual quantification.
- Author
-
Dux-Santoy L, Rodríguez-Palomares JF, Teixidó-Turà G, Ruiz-Muñoz A, Casas G, Valente F, Servato ML, Galian-Gay L, Gutiérrez L, González-Alujas T, Fernández-Galera R, Evangelista A, Ferreira-González I, and Guala A
- Subjects
- Aorta, Aorta, Thoracic diagnostic imaging, Humans, Observer Variation, Reproducibility of Results, Computed Tomography Angiography, Tomography, X-Ray Computed
- Abstract
Objectives: Manual assessment of aortic diameters on double-oblique reformatted computed tomography angiograms (CTA) is considered the current standard, although the reproducibility for growth rates has not been reported. Deformable registration of CTA has been proposed to provide 3D aortic diameters and growth maps, but validation is lacking. This study aimed to quantify accuracy and inter-observer reproducibility of registration-based and manual assessment of aortic diameters and growth rates., Methods: Forty patients with ≥ 2 CTA acquired at least 6 months apart were included. Aortic diameters and growth rate were obtained in the aortic root and the entire thoracic aorta using deformable image registration by two independent observers, and compared with the current standard at typical anatomical landmarks., Results: Compared with manual assessment, the registration-based technique presented low bias (0.46 mm), excellent agreement (ICC = 0.99), and similar inter-observer reproducibility (ICC = 0.99 for both) for aortic diameters; and low bias (0.10 mm/year), good agreement (ICC = 0.82), and much higher inter-observer reproducibility for growth rates (root: ICC = 0.96 vs 0.68; thoracic aorta: ICC = 0.96 vs 0.80). Registration-based growth rate reproducibility over a 6-month-long follow-up was similar to that obtained by manual assessment after 2.7 years (LoA = [- 0.01, 0.33] vs [- 0.13, 0.21] mm/year, respectively). Mapping of diameter and growth rate was highly reproducible (ICC > 0.9) in the whole thoracic aorta., Conclusions: Registration-based assessment of aortic dilation on CTA is accurate and substantially more reproducible than the current standard, even at follow-up as short as 6 months, and provides robust 3D mapping of aortic diameters and growth rates beyond the pre-established anatomic landmarks., Key Points: • Registration-based semi-automatic assessment of progressive aortic dilation on CTA is accurate and substantially more reproducible than the current standard. • The registration-based technique allows robust growth rate assessment at follow-up as short as 6 months, with a similar reproducibility to that obtained by manual assessment at around 3 years. • The use of image registration provides robust 3D mapping of aortic diameters and growth rates beyond the pre-established anatomic landmarks., (© 2021. European Society of Radiology.)
- Published
- 2022
- Full Text
- View/download PDF
38. Risk score for early risk prediction by cardiac magnetic resonance after acute myocardial infarction.
- Author
-
Marcos-Garcés V, Perez N, Gavara J, Lopez-Lereu MP, Monmeneu JV, Rios-Navarro C, de Dios E, Merenciano-González H, Gabaldon-Pérez A, Cànoves J, Racugno P, Bonanad C, Minana G, Nunez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, and Bodi V
- Subjects
- Aged, Humans, Magnetic Resonance Imaging, Cine, Magnetic Resonance Spectroscopy, Male, Middle Aged, Prognosis, Risk Factors, Stroke Volume, Ventricular Function, Left, Myocardial Infarction diagnostic imaging, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction diagnostic imaging
- Abstract
Background: Cardiac magnetic resonance (CMR) performed early after ST-segment elevation myocardial infarction (STEMI) can improve major adverse cardiac event (MACE) risk prediction. We aimed to create a simple clinical-CMR risk score for early MACE risk stratification in STEMI patients., Methods: We performed a multicenter prospective registry of reperfused STEMI patients (n = 1118) in whom early (1-week) CMR-derived left ventricular ejection fraction (LVEF), infarct size and microvascular obstruction (MVO) were quantified. MACE was defined as a combined clinical endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (NF-MI) or re-admission for acute decompensated heart failure (HF)., Results: During a median follow-up of 5.52 [2.63-7.44] years, 216 first MACE (58 CV deaths, 71 NF-MI and 87 HF) were registered. Mean age was 59.3 ± 12.3 years and most patients (82.8%) were male. Based on the four variables independently associated with MACE, we computed an 8-point risk score: time to reperfusion >4.15 h (1 point), GRACE risk score > 155 (3 points), CMR-LVEF <40% (3 points), and MVO >1.5 segments (1 point). This score permitted MACE risk stratification: MACE per 100 person-years was 1.96 in the low-risk category (0-2 points), 5.44 in the intermediate-risk category (3-5 points), and 19.7 in the high-risk category (6-8 points): p < 0.001 in multivariable Cox survival analysis., Conclusions: A novel risk score including clinical (time to reperfusion >4.15 h and GRACE risk score > 155) and CMR (LVEF <40% and MVO >1.5 segments) variables allows for simple and straightforward MACE risk stratification early after STEMI. External validation should confirm the applicability of the risk score., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
39. Multimodality Cardiac Imaging in Cardiomyopathies: From Diagnosis to Prognosis.
- Author
-
Casas G and Rodríguez-Palomares JF
- Abstract
Cardiomyopathies are a group of structural and/or functional myocardial disorders which encompasses hypertrophic, dilated, arrhythmogenic, restrictive, and other cardiomyopathies. Multimodality cardiac imaging techniques are the cornerstone of cardiomyopathy diagnosis; transthoracic echocardiography should be the first-line imaging modality due to its availability, and diagnosis should be confirmed by cardiovascular magnetic resonance, which will provide more accurate morphologic and functional information, as well as extensive tissue characterization. Multimodality cardiac imaging techniques are also essential in assessing the prognosis of patients with cardiomyopathies; left ventricular ejection fraction and late gadolinium enhancement are two of the main variables used for risk stratification, and they are incorporated into clinical practice guidelines. Finally, periodic testing with cardiac imaging techniques should also be performed due to the evolving and progressive natural history of most cardiomyopathies.
- Published
- 2022
- Full Text
- View/download PDF
40. Wall Shear Stress Predicts Aortic Dilation in Patients With Bicuspid Aortic Valve.
- Author
-
Guala A, Dux-Santoy L, Teixido-Tura G, Ruiz-Muñoz A, Galian-Gay L, Servato ML, Valente F, Gutiérrez L, González-Alujas T, Johnson KM, Wieben O, Casas-Masnou G, Sao Avilés A, Fernandez-Galera R, Ferreira-Gonzalez I, Evangelista A, and Rodríguez-Palomares JF
- Subjects
- Aortic Valve diagnostic imaging, Dilatation, Hemodynamics, Humans, Predictive Value of Tests, Bicuspid Aortic Valve Disease, Heart Valve Diseases
- Abstract
Objectives: This study sought to assess the predictive value of wall shear stress (WSS) for colocalized ascending aorta (AAo) growth rate (GR) in patients with bicuspid aortic valve (BAV)., Background: BAV is associated with AAo dilation, but there is limited knowledge about possible predictors of aortic dilation in patients with BAV. An increased WSS has been related to aortic wall damage in patients with BAV, but no previous prospective study tested its predictive value for dilation rate. Recently, a registration-based technique for the semiautomatic mapping of aortic GR has been presented and validated., Methods: Forty-seven patients with BAV free from valvular dysfunction prospectively underwent 4-dimensional flow cardiac magnetic resonance to compute WSS and subsequent follow-up with 2 electrocardiogram-gated high-resolution contrast-enhanced computed tomography angiograms for GR assessment., Results: During a median follow-up duration of 43 months, mid AAo GR was 0.24 mm/year. WSS and its circumferential component showed statistically significant association with mid AAo GR in bivariate (P = 0.049 and P = 0.014, respectively) and in multivariate analysis corrected for stroke volume and either baseline AAo diameter (P = 0.046 and P = 0.014, respectively) or z-score (P = 0.036 and P = 0.012, respectively). GR mapping further detailed that GR was heterogeneous in the AAo and that circumferential WSS, but not WSS magnitude, showed statistically significant positive associations with GR in the regions with the fastest growth., Conclusions: 4D flow cardiac magnetic resonance-derived WSS and, in particular, its circumferential component predict progressive dilation of the ascending aorta in patients with BAV. Thus, the assessment of WSS may be considered in the follow-up of these patients., Competing Interests: Funding Support and Author Disclosures This study was supported by funding from the Instituto de Salud Carlos III (projects PI14/01062, PI17/00381 and PI20/01727); the Spanish Ministry of Science, Innovation, and Universities (RTC2019-007280-1), the Spanish Society of Cardiology (SEC/FEC-INV-CLI 20/015 and SEC/FEC-INV-CLI 21/030); and the Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV). Dr Guala has received funding from the Spanish Ministry of Science, Innovation, and Universities (IJC2018-037349-I). Dr Johnson has received research grants from GE Healthcare through the University of Wisconsin-Madison (no personal compensation). Dr Wieben has received research grants from GE Healthcare through the University of Wisconsin-Madison (no personal compensation). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Reply: A Promising Step Forward in LVNC Risk Stratification, But How Much Trabeculation Can Be Normal?
- Author
-
Rodríguez-Palomares JF, Casas G, Guala A, Limeres J, and Ferreira-González I
- Subjects
- Heart Ventricles, Humans, Risk Assessment, Isolated Noncompaction of the Ventricular Myocardium
- Published
- 2021
- Full Text
- View/download PDF
42. Leaflet fusion length is associated with aortic dilation and flow alterations in non-dysfunctional bicuspid aortic valve.
- Author
-
Guala A, Evangelista A, Teixido-Tura G, La Mura L, Dux-Santoy L, Ruiz-Muñoz A, Valente F, Galian-Gay L, Gutiérrez L, González-Alujas T, Dentamaro I, Johnson KM, Wieben O, Sao Avilés A, Ferreira-Gonzalez I, and Rodríguez-Palomares JF
- Subjects
- Aortic Valve diagnostic imaging, Dilatation, Humans, Reproducibility of Results, Bicuspid Aortic Valve Disease, Heart Valve Diseases diagnostic imaging
- Abstract
Objective: Bicuspid aortic valve (BAV), the most common congenital valve defect, is associated with increased risk of aortic dilation and related complications; however, current risk assessment is not effective. Most of BAV have three leaflets with a fusion between two of them of variable length. This study aimed to ascertain whether the extent of leaflet fusion (often called raphe) is related to aortic dilation and flow abnormalities in BAV with no significant valvular dysfunction., Methods: One hundred and twenty BAV patients with no significant valvular dysfunction or history of surgical repair or aortic valve replacement were consecutively and prospectively enrolled (September 2014-October 2018). Cardiac magnetic resonance protocol included a 4D flow sequence for haemodynamic assessment. Moreover, a stack of double-oblique cine images of the aortic valve were used to quantify fusion length (in systole) and leaflet length (diastole). Inter- and intra-observer reproducibility was tested in 30 randomly selected patients., Results: Aortic valve leaflet fusion was measurable in 112 of 120 (93%) cases with good reproducibility (ICC = 0.826). Fusion length varied greatly (range: 2.3-15.4 mm; mean: 7.8 ± 3.2 mm). After correction for demographic and clinical conditions, fusion length was independently associated with diameter and z-score at the sinus of Valsalva (p = 0.002 and p = 0.002, respectively) and ascending aorta (p = 0.028 and p = 0.046). Fusion length was positively related to flow asymmetry, vortices and circumferential wall shear stress, thereby possibly providing a pathophysiological link with aortic dilation., Conclusions: Aortic valve fusion length is related to aortic dilation and flow abnormalities in BAV patients., Key Points: • The length of the fusion between leaflets in non-dysfunctional bicuspid aortic valves varies substantially and can be reliably measured by cine CMR. • Aortic valve leaflet fusion length is independently related to aortic sinus and ascending aorta diameter. • Increased flow asymmetry, circumferential wall shear stress and presence of vortices are positively related to aortic valve leaflet fusion length., (© 2021. European Society of Radiology.)
- Published
- 2021
- Full Text
- View/download PDF
43. Geometric, Biomechanic and Haemodynamic Aortic Abnormalities Assessed by 4D Flow Cardiovascular Magnetic Resonance in Patients Treated by TEVAR Following Blunt Traumatic Thoracic Aortic Injury.
- Author
-
Gil-Sala D, Guala A, Garcia Reyes ME, Azancot MA, Dux-Santoy L, Allegue Allegue N, Teixido Turà G, Goncalves Martins G, Ruiz Muñoz A, Constenla García I, Evangelista A, Tello Díaz C, Ferreira González I, Rodríguez-Palomares JF, and Bellmunt S
- Subjects
- Adult, Aorta, Thoracic diagnostic imaging, Blood Vessel Prosthesis Implantation, Cross-Sectional Studies, Endovascular Procedures, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pulse Wave Analysis, Wounds, Nonpenetrating physiopathology, Aorta, Thoracic injuries, Aorta, Thoracic surgery, Wounds, Nonpenetrating diagnostic imaging, Wounds, Nonpenetrating surgery
- Abstract
Objective: Thoracic endovascular aortic repair (TEVAR) is widely used for the treatment of patients with blunt traumatic thoracic aortic injury (BTAI). However, aortic haemodynamic and biomechanical implications of this intervention are poorly investigated. This study aimed to assess whether patients treated by TEVAR following BTAI have thoracic aortic abnormalities in geometry, stiffness, and haemodynamics., Methods: Patients with BTAI treated by TEVAR at Vall d'Hebron Hospital between 1999 and 2019 were compared with propensity score matched healthy volunteers (HVs). All subjects underwent cardiovascular magnetic resonance (CMR) comprising a 4D flow CMR sequence. Spatially resolved aortic diameter, length, volume, and curvature were assessed. Pulse wave velocity, distensibility, and longitudinal strain (all measurements of aortic stiffness) were determined regionally. Moreover, advanced haemodynamic descriptors were quantified: systolic flow reversal ratio (SFRR), quantifying backward flow during systole, and in plane rotational flow (IRF), measuring in plane strength of helical flow., Results: Twenty-six BTAI patients treated by TEVAR were included and matched with 26 HVs. They did not differ in terms of age, sex, and body surface area. Patients with TEVAR had a larger and longer ascending aorta (AAo) and marked abnormalities in local curvature. Aortic stiffness was greater in the aortic segments proximal and distal to TEVAR compared with controls. Moreover, TEVAR patients presented strongly altered flow dynamics compared with controls: a reduced IRF from the distal AAo to the proximal descending aorta and an increased SFRR in the whole thoracic aorta. These differences persisted adjusting for cardiovascular risk factors and were independent of time elapsed since TEVAR implantation., Conclusion: At long term follow up, previously healthy patients who underwent TEVAR implantation following BTAI had increased diameter, length and volume of the ascending aorta, and increased aortic stiffness and abnormal flow patterns in the whole thoracic aorta compared with matched controls. Further studies should address whether these alterations have clinical implications., (Copyright © 2021 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
44. Radiomics-Based Classification of Left Ventricular Non-compaction, Hypertrophic Cardiomyopathy, and Dilated Cardiomyopathy in Cardiovascular Magnetic Resonance.
- Author
-
Izquierdo C, Casas G, Martin-Isla C, Campello VM, Guala A, Gkontra P, Rodríguez-Palomares JF, and Lekadir K
- Abstract
Left Ventricular (LV) Non-compaction (LVNC), Hypertrophic Cardiomyopathy (HCM), and Dilated Cardiomyopathy (DCM) share morphological and functional traits that increase the diagnosis complexity. Additional clinical information, besides imaging data such as cardiovascular magnetic resonance (CMR), is usually required to reach a definitive diagnosis, including electrocardiography (ECG), family history, and genetics. Alternatively, indices of hypertrabeculation have been introduced, but they require tedious and time-consuming delineations of the trabeculae on the CMR images. In this paper, we propose a radiomics approach to automatically encode differences in the underlying shape, gray-scale and textural information in the myocardium and its trabeculae, which may enhance the capacity to differentiate between these overlapping conditions. A total of 118 subjects, including 35 patients with LVNC, 25 with HCM, 37 with DCM, as well as 21 healthy volunteers (NOR), underwent CMR imaging. A comprehensive radiomics characterization was applied to LV short-axis images to quantify shape, first-order, co-occurrence matrix, run-length matrix, and local binary patterns. Conventional CMR indices (LV volumes, mass, wall thickness, LV ejection fraction-LVEF-), as well as hypertrabeculation indices by Petersen and Jacquier, were also analyzed. State-of-the-art Machine Learning (ML) models (one-vs.-rest Support Vector Machine-SVM-, Logistic Regression-LR-, and Random Forest Classifier-RF-) were used for one-vs.-rest classification tasks. The use of radiomics models for the automated diagnosis of LVNC, HCM, and DCM resulted in excellent one-vs.-rest ROC-AUC values of 0.95 while generating these results without the need for the delineation of the trabeculae. First-order and texture features resulted to be among the most discriminative features in the obtained radiomics signatures, indicating their added value for quantifying relevant tissue patterns in cardiomyopathy differential diagnosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Izquierdo, Casas, Martin-Isla, Campello, Guala, Gkontra, Rodríguez-Palomares and Lekadir.)
- Published
- 2021
- Full Text
- View/download PDF
45. Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy.
- Author
-
Escobar-Lopez L, Ochoa JP, Mirelis JG, Espinosa MÁ, Navarro M, Gallego-Delgado M, Barriales-Villa R, Robles-Mezcua A, Basurte-Elorz MT, Gutiérrez García-Moreno L, Climent V, Jiménez-Jaimez J, Mogollón-Jiménez MV, Lopez J, Peña-Peña ML, García-Álvarez A, Brion M, Ripoll-Vera T, Palomino-Doza J, Tirón C, Idiazabal U, Brögger MN, García-Hernández S, Restrepo-Córdoba MA, Gonzalez-Lopez E, Méndez I, Sabater M, Villacorta E, Larrañaga-Moreira JM, Abecia A, Fernández AI, García-Pinilla JM, Rodríguez-Palomares JF, Gimeno-Blanes JR, Bayes-Genis A, Lara-Pezzi E, Domínguez F, and Garcia-Pavia P
- Subjects
- Adult, Aged, Arrhythmias, Cardiac physiopathology, Female, Genotype, Heart Ventricles, Humans, Longitudinal Studies, Male, Middle Aged, Retrospective Studies, Risk, Stroke Volume genetics, Treatment Outcome, Ventricular Dysfunction physiopathology, Ventricular Function, Left, Ventricular Remodeling, Cardiomyopathy, Dilated genetics, Genetic Variation, Heart Failure genetics
- Abstract
Background: The clinical relevance of genetic variants in nonischemic dilated cardiomyopathy (DCM) is unsettled., Objectives: The study sought to assess the prognostic impact of disease-causing genetic variants in DCM., Methods: Baseline and longitudinal clinical data from 1,005 genotyped DCM probands were retrospectively collected at 20 centers. A total of 372 (37%) patients had pathogenic or likely pathogenic variants (genotype positive) and 633 (63%) were genotype negative. The primary endpoint was a composite of major adverse cardiovascular events. Secondary endpoints were end-stage heart failure (ESHF), malignant ventricular arrhythmia (MVA), and left ventricular reverse remodeling (LVRR)., Results: After a median follow-up of 4.04 years (interquartile range: 1.70-7.50 years), the primary endpoint had occurred in 118 (31.7%) patients in the genotype-positive group and in 125 (19.8%) patients in the genotype-negative group (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.17-1.94; P = 0.001). ESHF occurred in 60 (16.1%) genotype-positive patients and in 55 (8.7%) genotype-negative patients (HR: 1.67; 95% CI: 1.16-2.41; P = 0.006). MVA occurred in 73 (19.6%) genotype-positive patients and in 77 (12.2%) genotype-negative patients (HR: 1.50; 95% CI: 1.09-2.07; P = 0.013). LVRR occurred in 39.6% in the genotype-positive group and in 46.2% in the genotype-negative group (P = 0.047). Among individuals with baseline left ventricular ejection fraction ≤35%, genotype-positive patients exhibited more major adverse cardiovascular events, ESHF, and MVA than their genotype-negative peers (all P < 0.02). LVRR and clinical outcomes varied depending on the underlying affected gene., Conclusions: In this study, DCM patients with pathogenic or likely pathogenic variants had worse prognosis than genotype-negative individuals. Clinical course differed depending on the underlying affected gene., Competing Interests: Funding Support and Author Disclosures This work was supported by grants from the following institutions: the Instituto de Salud Carlos III (AC16/0014, PI18/0004, PI20/0320) and the European Union (GENPROVIC project from ERA-CVD framework). The Hospital Universitario Puerta de Hierro and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart). All authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction.
- Author
-
Casas G, Limeres J, Oristrell G, Gutierrez-Garcia L, Andreini D, Borregan M, Larrañaga-Moreira JM, Lopez-Sainz A, Codina-Solà M, Teixido-Tura G, Sorolla-Romero JA, Fernández-Álvarez P, González-Carrillo J, Guala A, La Mura L, Soler-Fernández R, Sao Avilés A, Santos-Mateo JJ, Marsal JR, Ribera A, de la Pompa JL, Villacorta E, Jiménez-Jáimez J, Ripoll-Vera T, Bayes-Genis A, Garcia-Pinilla JM, Palomino-Doza J, Tiron C, Pontone G, Bogaert J, Aquaro GD, Gimeno-Blanes JR, Zorio E, Garcia-Pavia P, Barriales-Villa R, Evangelista A, Masci PG, Ferreira-González I, and Rodríguez-Palomares JF
- Subjects
- Adult, Aged, Arrhythmias, Cardiac etiology, Embolism etiology, Female, Heart Failure etiology, Humans, Isolated Noncompaction of the Ventricular Myocardium complications, Isolated Noncompaction of the Ventricular Myocardium genetics, Longitudinal Studies, Male, Middle Aged, Retrospective Studies, Risk Assessment, Spain epidemiology, Young Adult, Arrhythmias, Cardiac epidemiology, Embolism epidemiology, Heart Failure epidemiology, Isolated Noncompaction of the Ventricular Myocardium mortality, Patient-Specific Modeling
- Abstract
Background: Left ventricular noncompaction (LVNC) is a heterogeneous entity with uncertain prognosis., Objectives: This study sought to develop and validate a prediction model of major adverse cardiovascular events (MACE) and to identify LVNC cases without events during long-term follow-up., Methods: This is a retrospective longitudinal multicenter cohort study of consecutive patients fulfilling LVNC criteria by echocardiography or cardiovascular magnetic resonance. MACE were defined as heart failure (HF), ventricular arrhythmias (VAs), systemic embolisms, or all-cause mortality., Results: A total of 585 patients were included (45 ± 20 years of age, 57% male). LV ejection fraction (LVEF) was 48% ± 17%, and 18% presented late gadolinium enhancement (LGE). After a median follow-up of 5.1 years, MACE occurred in 223 (38%) patients: HF in 110 (19%), VAs in 87 (15%), systemic embolisms in 18 (3%), and 34 (6%) died. LVEF was the main variable independently associated with MACE (P < 0.05). LGE was associated with HF and VAs in patients with LVEF >35% (P < 0.05). A prediction model of MACE was developed using Cox regression, composed by age, sex, electrocardiography, cardiovascular risk factors, LVEF, and family aggregation. C-index was 0.72 (95% confidence interval: 0.67-0.75) in the derivation cohort and 0.72 (95% confidence interval: 0.71-0.73) in an external validation cohort. Patients with no electrocardiogram abnormalities, LVEF ≥50%, no LGE, and negative family screening presented no MACE at follow-up., Conclusions: LVNC is associated with an increased risk of heart failure and ventricular arrhythmias. LVEF is the variable most strongly associated with MACE; however, LGE confers additional risk in patients without severe systolic dysfunction. A risk prediction model is developed and validated to guide management., Competing Interests: Funding Support and Author Disclosures The project was partially funded by a grant from the Catalan Society of Cardiology (Barcelona, Spain). Hospital Universitario Virgen de la Arrixaca (Murcia, Spain) was supported by a grant from the Foundation Marató TV3 (218/C/2015) (Barcelona, Spain). Hospital Universitario y Politécnico La Fe (Valencia, Spain) was partially supported by Fondo Europeo de Desarrollo Regional (“Unión Europea, Una forma de hacer Europa”) (Madrid, Spain) and the Instituto de Salud Carlos III (La Fe Biobank PT17/0015/0043) (Madrid, Spain). Dr Guala was supported by funding from the Spanish Ministry of Science, Innovation and Universities (IJC2018-037349-I) (Madrid, Spain). Dr La Mura was supported by a research grant from the Cardiopath PhD program (Naples, Italy). Prof de la Pompa was supported by grants PID2019-104776RB-I00 and CB16/11/00399 (CIBER CV) from the Spanish Ministry of Science, Innovation and Universities. Dr Bayes-Genis was supported by grants from CIBER Cardiovascular (CB16/11/00403 and 16/11/00420) (Madrid, Spain) and AdvanceCat 2014-2020 (Barcelona, Spain); and has received advisory board and lecture fees from Novartis, Boehringer Ingelheim, Vifor, Roche Diagnostics, and Critical Diagnostics. Dr Pontone has received speaker honorarium and/or institutional research grants from GE Healthcare, Bracco, Boehringer Ingelheim, and HeartFlow. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
47. Predictors of cardiovascular outcomes after surgery in severe tricuspid regurgitation: clinical, imaging and hemodynamic prospective study.
- Author
-
Rodríguez-Palomares JF, Lozano-Torres J, Dentamaro I, Valente FX, Avilés AS, García-Moreno LG, Sabaté PR, Otaegui I, Rosique BM, Calabria HC, Masip AE, Mas PT, Ferreira-González I, and González-Alujas MT
- Subjects
- Aged, Echocardiography, Female, Hemodynamics, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Heart Valve Prosthesis Implantation, Tricuspid Valve Insufficiency diagnosis, Tricuspid Valve Insufficiency surgery
- Abstract
Introduction and Objectives: Severe tricuspid regurgitation (TR) is a prevalent valve disease with a high mortality rate. Current guidelines do not define specific thresholds at which patients should be considered for surgery or percutaneous procedures. Thus, patients are usually referred for intervention at a late stage of the disease. This study aimed to assess predictors of cardiovascular outcomes in a prospective cohort of patients with severe TR referred for surgery., Methods: This was an observational, prospective, nonrandomized study. All patients underwent surgery for severe TR based on current clinical guidelines. Complete anamnesis, blood test, echocardiogram, cardiovascular magnetic resonance and right and left catheterization were performed. Patients were followed up in the outpatient department and a combined endpoint (hospitalization for heart failure and cardiovascular mortality) was registered., Results: Forty-three consecutive patients were included (age: 66.9 ± 9.6 years, 67.4% female). Tricuspid annuloplasty was performed in all patients. After a median follow-up of 38 months, 12 patients (27.9%) showed the combined endpoint and 7 (16.3%) died. Above all clinical, blood and imaging data, the indexed right ventricular end-diastolic volume constituted the best predictor of the combined endpoint (HR, 1.1; P = .02) and cardiovascular mortality (HR, 1.1; P = .05). Furthermore, indexed right ventricular end-diastolic volume was associated with TR recurrence after surgery, with no impact on clinical outcomes., Conclusions: In patients with severe TR referred for surgery, right ventricular remodeling assessed by cardiovascular magnetic resonance constituted the best independent predictor of cardiovascular outcomes at follow-up., (Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
48. Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure.
- Author
-
Akhtar MM, Lorenzini M, Pavlou M, Ochoa JP, O'Mahony C, Restrepo-Cordoba MA, Segura-Rodriguez D, Bermúdez-Jiménez F, Molina P, Cuenca S, Ader F, Larrañaga-Moreira JM, Sabater-Molina M, Garcia-Alvarez MI, Arantzamendi LG, Truszkowska G, Ortiz-Genga M, Ruiz IS, Nielsen SK, Rasmussen TB, Robles Mezcua A, Alvarez-Rubio J, Eiskjaer H, Gautel M, Garcia-Pinilla JM, Ripoll-Vera T, Mogensen J, Limeres Freire J, Rodríguez-Palomares JF, Peña-Peña ML, Rangel-Sousa D, Palomino-Doza J, Arana Achaga X, Bilinska Z, Zamarreño Golvano E, Climent V, Peñalver MN, Barriales-Villa R, Charron P, Yotti R, Zorio E, Jiménez-Jáimez J, Garcia-Pavia P, and Elliott PM
- Subjects
- Adult, Cardiomyopathy, Dilated mortality, Cardiomyopathy, Dilated physiopathology, Cardiomyopathy, Dilated therapy, Codon, Nonsense, Connectin genetics, Defibrillators, Implantable, Female, Heart Failure mortality, Heart Failure physiopathology, Heart Failure therapy, Heart Transplantation statistics & numerical data, Humans, Male, Middle Aged, Mutation, Stroke Volume, Tachycardia, Ventricular epidemiology, Tachycardia, Ventricular physiopathology, Ventricular Dysfunction, Left physiopathology, Cardiomyopathy, Dilated genetics, Death, Sudden, Cardiac prevention & control, Filamins genetics, Heart Failure genetics, Tachycardia, Ventricular genetics, Ventricular Dysfunction, Left genetics
- Abstract
Importance: Truncating variants in the gene encoding filamin C (FLNCtv) are associated with arrhythmogenic and dilated cardiomyopathies with a reportedly high risk of ventricular arrhythmia., Objective: To determine the frequency of and risk factors associated with adverse events among FLNCtv carriers compared with individuals carrying TTN truncating variants (TTNtv)., Design, Setting, and Participants: This cohort study recruited 167 consecutive FLNCtv carriers and a control cohort of 244 patients with TTNtv matched for left ventricular ejection fraction (LVEF) from 19 European cardiomyopathy referral units between 1990 and 2018. Data analyses were conducted between June and October, 2020., Main Outcomes and Measures: The primary end point was a composite of malignant ventricular arrhythmia (MVA) (sudden cardiac death, aborted sudden cardiac death, appropriate implantable cardioverter-defibrillator shock, and sustained ventricular tachycardia) and end-stage heart failure (heart transplant or mortality associated with end-stage heart failure). The secondary end point comprised MVA events only., Results: In total, 167 patients with FLNCtv were studied (55 probands [33%]; 89 men [53%]; mean [SD] age at baseline evaluation, 43 [18] years). For a median follow-up of 20 months (interquartile range, 7-60 months), 29 patients (17.4%) reached the primary end point (19 patients with MVA and 10 patients with end-stage heart failure). Eight (44%) arrhythmic events occurred among individuals with baseline mild to moderate left ventricular systolic dysfunction (LVSD) (LVEF = 36%-49%). Univariable risk factors associated with the primary end point included proband status, LVEF decrement per 10%, ventricular ectopy (≥500 in 24 hours) and myocardial fibrosis detected on cardiac magnetic resonance imaging. The LVEF decrement (hazard ratio [HR] per 10%, 1.83 [95% CI, 1.30-2.57]; P < .001) and proband status (HR, 3.18 [95% CI, 1.12-9.04]; P = .03) remained independent risk factors on multivariable analysis (excluding myocardial fibrosis and ventricular ectopy owing to case censoring). There was no difference in freedom from MVA between FLNCtv carriers with mild to moderate or severe (LVEF ≤35%) LVSD (HR, 1.29 [95% CI, 0.45-3.72]; P = .64). Carriers of FLNCtv with impaired LVEF at baseline evaluation (n = 69) had reduced freedom from MVA compared with 244 TTNtv carriers with similar baseline LVEF (for mild to moderate LVSD: HR, 16.41 [95% CI, 3.45-78.11]; P < .001; for severe LVSD: HR, 2.47 [95% CI, 1.04-5.87]; P = .03)., Conclusions and Relevance: The high frequency of MVA among patients with FLNCtv with mild to moderate LVSD suggests that higher LVEF values than those currently recommended should be considered for prophylactic implantable cardioverter-defibrillator therapy in FLNCtv carriers.
- Published
- 2021
- Full Text
- View/download PDF
49. Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.
- Author
-
Restrepo-Cordoba MA, Wahbi K, Florian AR, Jiménez-Jáimez J, Politano L, Arad M, Climent-Paya V, Garcia-Alvarez A, Hansen RB, Larrañaga-Moreira JM, Kubanek M, Lopes LR, Ros A, Jurcut R, Rasmussen TB, Ruiz-Guerrero L, Pribe-Wolferts R, Palomino-Doza J, Bilinska Z, Rodríguez-Palomares JF, Van Loon RLE, Basurte Elorz MT, Quarta G, Robledo Iñarritu M, Verdonschot JAJ, Stojkovic T, Shomanova Z, Bermudez-Jimenez F, Palladino A, Freimark D, García-Álvarez MI, Jorda P, Dominguez F, Ochoa JP, Girolami F, Brugada R, Meder B, Barriales-Villa R, Mogensen J, Laforêt P, Yilmaz A, Elliott P, and Garcia-Pavia P
- Subjects
- Adolescent, Adult, Dystrophin genetics, Female, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Stroke Volume, Ventricular Function, Left, Young Adult, Cardiomyopathy, Dilated epidemiology, Cardiomyopathy, Dilated genetics, Heart Failure epidemiology, Muscular Diseases
- Abstract
Aims: Dilated cardiomyopathy (DCM) associated with dystrophin gene (DMD) mutations in individuals with mild or absent skeletal myopathy is often indistinguishable from other DCM forms. We sought to describe the phenotype and prognosis of DMD associated DCM in DMD mutation carriers without severe skeletal myopathy., Methods and Results: At 26 European centres, we retrospectively collected clinical characteristics and outcomes of 223 DMD mutation carriers (83% male, 33 ± 15 years). A total of 112 individuals (52%) had DCM at first evaluation [n = 85; left ventricular ejection fraction (LVEF) 34 ± 11.2%] or developed DCM (n = 27; LVEF 41.3 ± 7.5%) after a median follow-up of 96 months (interquartile range 5-311 months). DCM penetrance was 45% in carriers older than 40 years. DCM appeared earlier in males and was independent of the type of mutation, presence of skeletal myopathy, or elevated serum creatine kinase levels. Major adverse cardiac events (MACE) occurred in 22% individuals with DCM, 18% developed end-stage heart failure and 9% sudden cardiac death or equivalent. Skeletal myopathy was not associated with survival free of MACE in patients with DCM. Decreased LVEF and increased left ventricular end-diastolic diameter at baseline were associated with MACE. Individuals without DCM had favourable prognosis without MACE or death during follow-up., Conclusions: DMD-associated DCM without severe skeletal myopathy is characterized by incomplete penetrance but high risk of MACE, including progression to end-stage heart failure and ventricular arrhythmias. DCM onset is the major determinant of prognosis with similar survival regardless of the presence of skeletal myopathy., (© 2021 European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
50. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction.
- Author
-
Inserte J, Barrabés JA, Aluja D, Otaegui I, Bañeras J, Castellote L, Sánchez A, Rodríguez-Palomares JF, Pineda V, Miró-Casas E, Milà L, Lidón RM, Sambola A, Valente F, Rafecas A, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Buera I, Delgado-Tomás S, Beneítez D, and Ferreira-González I
- Abstract
In patients with a first anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention, iron deficiency (ID) was associated with larger infarcts, more extensive microvascular obstruction, and higher frequency of adverse left ventricular remodeling as assessed by cardiac magnetic resonance imaging. In mice, an ID diet reduced the activity of the endothelial nitric oxide synthase/soluble guanylate cyclase/protein kinase G pathway in association with oxidative/nitrosative stress and increased infarct size after transient coronary occlusion. Iron supplementation or administration of an sGC activator before ischemia prevented the effects of the ID diet in mice. Not only iron excess, but also ID, may have deleterious effects in the setting of ischemia and reperfusion., Competing Interests: This study was funded by Instituto de Salud Carlos III, Spain, through the project PI16/00232 and the research network CIBERCV (CB16/11/00479), both cofunded by European Regional Development Fund, and by the Sociedad Española de Cardiología (Proyecto de Investigación Traslacional en Cardiología 2016). The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.